Psychopharmacology and Psychiatry Updates: Recent Episodes
Psychopharmacology Institute
Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.
In this episode, we discuss evidence-based strategies for safely tapering patients off benzodiazepines, including cut-and-hold and microtapering techniques. What's the best approach when commercial dosage forms limit gradual reductions?
Faculty: Alexis Ritvo Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Strategies for Successful Benzodiazepine Deprescribing
- Techniques for Successful Benzodiazepine Tapering
In this episode, we explore lithium's surprising positive effect on bone mineral density in patients with bipolar disorder. Could the medication many psychiatrists use as a mood stabilizer also be protecting patients from osteoporosis?
Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CME: Quick Take Vol. 68
- Can Lithium Protect Against Osteoporosis?
In this episode, we explore evidence-based strategies for successful benzodiazepine tapering with addiction psychiatrist Dr. Alexis Ritvo. How can clinicians minimize withdrawal effects while supporting patients through this challenging process?
Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 1.25 CMEs: Strategies for Successful Benzodiazepine Deprescribing
- Understanding the Principles of Benzodiazepine Tapering
In this episode, we explore compelling evidence from the UK Biobank showing how vitamin D deficiency may increase dementia risk by up to 25%. Could this affordable supplement be an essential piece of your brain health strategy?
Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CME: Quick Take Vol. 68
- Can Vitamin D Deficiency Increase the Risk of Alzheimer's Disease?
In this episode, we explore the complex process of benzodiazepine deprescribing, examining when and how to help patients reduce or discontinue these medications. How can clinicians balance the benefits of deprescription against the challenges of withdrawal?
Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CMEs: Strategies for Successful Benzodiazepine Deprescribing
- Benzodiazepine Deprescription: Indications, Benefits, and Risks
In this episode, we explore the unique considerations for using long-acting injectable antipsychotics in women with schizophrenia. How might hormonal fluctuations throughout a woman's life impact treatment decisions for schizophrenia?
Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CME: Quick Take Vol. 68
- Long-Acting Antipsychotics: An Option for Women with Schizophrenia?
In this episode, we explore the challenges and current guidelines for benzodiazepine use in pregnancy, breastfeeding, and adolescence. When is it appropriate to continue benzodiazepines during pregnancy, and what alternatives should clinicians consider?
Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: Understanding Benzodiazepine Prescribing: A Clinician's Guide
- Consequences of Benzodiazepine Use in Pregnancy, Breastfeeding, and Adolescence
In this episode, we explore benzodiazepine use disorder, distinguishing between physical dependence and addiction while examining practical strategies for safe prescribing. Did you know only 1.5% of benzodiazepine users actually develop a use disorder?
Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: Understanding Benzodiazepine Prescribing: A Clinician's Guide
- Benzodiazepine Use Disorder
In this episode, we explore the potential role of the probiotic Akkermansia muciniphila in managing olanzapine-induced weight gain. Could this tiny gut bacterium be the key to maintaining metabolic health while on antipsychotics?
Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CME: Quick Take Vol. 67
- Olanzapine-Induced Weight Gain: Can Akkermansia Muciniphila Help?
In this episode, we explore the dangerous risks of benzodiazepine use, focusing on the potentially lethal combination with opioids, cognitive impairment, increased accident risk, and fall hazards. Did you know that benzodiazepines combined with opioids increase overdose risk fivefold in the first 90 days?
Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: Understanding Benzodiazepine Prescribing: A Clinician's Guide
- Understanding the Major Risks of Benzodiazepine Use
In this episode, we explore the latest research on antidepressant discontinuation symptoms, revealing that about 14% of patients experience these effects when stopping medication. Which antidepressants are most likely to cause these "brain zaps" and other withdrawal symptoms?
Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CME: Quick Take Vol. 67
- Which Antidepressants Have the Highest Risk of Discontinuation Symptoms?
In this episode, we discuss the appropriate use of benzodiazepines, focusing on evidence-based indications and optimal medication selection. Did you know that alprazolam has unique properties that make it more addictive than other benzodiazepines?
Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: Understanding Benzodiazepine Prescribing: A Clinician's Guide
- Appropriate Benzodiazepine Use: Indications and Optimal Selection
In this episode, we explore the evidence behind Transcranial Magnetic Stimulation (TMS) for depression, from early clinical trials to real-world effectiveness. What makes some patients respond better to TMS than others? We discuss response rates, treatment protocols, and the exciting development of faster treatment options.
Faculty: Simon Kung, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: TMS in Psychiatry: Innovations and Best Practices
- Exploring the Evidence of TMS for Depression
In this episode, we explore the crucial aspects of patient selection for Transcranial Magnetic Stimulation (TMS) in treating depression. We discuss insurance criteria, contraindications, and practical considerations. Did you know that while TMS was FDA-approved in 2008, it wasn't widely accessible until Medicare began covering it in 2014?
Faculty: Simon Kung, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: TMS in Psychiatry: Innovations and Best Practices
- Optimizing Patient Selection for TMS Treatment
In this episode, we explore a landmark Finnish study examining the long-term risk of agranulocytosis in patients taking clozapine. The research followed 62,000 patients over 22 years, providing crucial data about this rare but serious side effect. Could these findings change how we approach clozapine prescribing and monitoring requirements?
Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.75 CME: Quick Take Vol. 66
- Does Clozapine's Agranulocytosis Risk Persist Beyond Initial Treatment Period?
In this episode, we explore Transcranial Magnetic Stimulation (TMS) as a treatment option for Obsessive-Compulsive Disorder (OCD). We discuss the FDA-approved devices, unique protocols, and why patients need their anxiety triggered before each session. Did you know TMS for OCD targets a completely different brain region than TMS for depression?
Faculty: Simon Kung, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: TMS in Psychiatry: Innovations and Best Practices
- Exploring the Evidence of TMS for OCD
In this episode, we explore donanemab, a groundbreaking monoclonal antibody treatment for Alzheimer's disease. We discuss its efficacy in reducing beta-amyloid plaques, unique treatment duration protocol, and safety considerations. Could this time-limited treatment approach revolutionize how we manage Alzheimer's progression?
Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.75 CMEs: Quick Take Vol. 66
- Can Donanemab Slow Alzheimer's Progression?
In this episode, we explore a groundbreaking Danish registry study that challenges common beliefs about long-term benzodiazepine use and dose escalation patterns. Are our concerns about inevitable tolerance and dependence justified? The study's findings might surprise you and reshape prescribing practices.
Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.75 CME: Quick Take Vol. 65
- Do Benzodiazepine Users Escalate Doses Over Time?
In this episode, we explore the side effects and safety considerations of Transcranial Magnetic Stimulation (TMS) therapy in psychiatry. Did you know that despite common concerns, fewer than 2% of patients discontinue TMS due to discomfort? We'll discuss everything from common side effects to practical management strategies.
Faculty: Simon Kung, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: TMS in Psychiatry: Innovations and Best Practices
- Assessing the Potential Side Effects of TMS
In this episode, we explore the crucial interaction between SSRIs and oral anticoagulants, examining a groundbreaking 23-year study of over 330,000 patients. Does combining these medications significantly increase bleeding risk, and if so, how can we safely manage patients who need both treatments?
Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.75 CME: Quick Take Vol. 65
- Can SSRIs Be Safely Prescribed With Oral Anticoagulants?
In this episode, we explore the safe use and monitoring of lamotrigine, focusing on cardiac risks and when EKG monitoring is necessary. Did you know that reducing lamotrigine dose doesn't actually mitigate cardiac risks but could increase the risk of psychiatric destabilization?
Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.5 CME: Lamotrigine: From Current Indications to Cardiac Side Effects
- Strategies for Safe Usage and Proper Monitoring of Lamotrigine
In this episode, we explore the often-overlooked phenomenon of antipsychotic withdrawal, examining new findings from the world's largest drug safety database. Could some cases of apparent psychotic relapse actually be withdrawal symptoms in disguise? We discuss common withdrawal effects, risk factors, and evidence-based strategies for safe medication discontinuation.
Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.75 CME: Quick Take Vol. 64
- Antipsychotic Withdrawal Syndrome: Symptoms, Risks, and Prevention Strategies
In this episode, we explore lamotrigine's cardiac side effects, focusing on QTc prolongation and QRS widening. How concerned should psychiatrists be about the FDA warning regarding lamotrigine's cardiac effects? We examine the evidence behind these concerns and discuss practical implications for clinical practice.
Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.5 CME: Lamotrigine: From Current Indications to Cardiac Side Effects
- Lamotrigine Effect on QTc Prolongation and QRS Widening
In this episode, we examine a groundbreaking Danish study that challenges the conventional belief that sedative medications increase fall risk in older adults. Could untreated insomnia, rather than the medications used to treat it, be the real culprit behind falls in elderly patients?
Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.75 CME: Quick Take Vol. 64
- Insomnia in the Elderly: Do Sedatives Increase or Decrease Fall Risk?
In this episode, we explore lamotrigine's side effects and special considerations, particularly focusing on identifying dangerous skin reactions, pregnancy considerations, and overdose risks. Did you know that Asian populations may require special genetic screening before starting lamotrigine due to increased skin reaction risks?
Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.5 CME: Lamotrigine: From Current Indications to Cardiac Side Effects
- Lamotrigine: Side Effects and Special Considerations
In this episode, we explore the efficacy and safety of iloperidone in treating bipolar disorder, examining new phase 3 trial data that reveals both promising results for mania symptoms and important considerations about side effects. Can this antipsychotic's favorable EPS profile outweigh its metabolic risks?
Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.75 CMEs: Quick Take Vol. 63
- Iloperidone: A Potential Treatment Option for Bipolar Mania
In this episode, we explore the vital aspects of prescribing lamotrigine, from its mechanisms to titration schedules. Did you know that birth control pills can cut lamotrigine levels in half within just one week? Understanding these interactions is crucial for safe and effective treatment.
Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.5 CME: Lamotrigine: From Current Indications to Cardiac Side Effects
- Understanding Lamotrigine Mechanisms and Titration Schedule
In this episode, we explore the pharmacological management of agitation in emergency settings, focusing on benzodiazepines and the novel medication dexmedetomidine. Did you know there's now a sublingual option that works through an entirely different mechanism than traditional anti-agitation medications?
Faculty: Scott Zeller, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: The Psychopharmacology of Agitation: Managing Behavioral Emergencies
- The Role of Benzodiazepines and Dexmedetomidine in Managing Agitation
In this episode, we explore KarXT, a groundbreaking experimental antipsychotic that works through the cholinergic system rather than dopamine pathways. Could this novel approach revolutionize schizophrenia treatment by offering similar efficacy to current antipsychotics but without the motor side effects?
Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.75 CMEs: Quick Take Vol. 63
- Xanomeline-Trospium (KarXT) Shows Efficacy in Phase 3 Trial for Schizophrenia
In this episode, we explore evidence-based pharmacologic strategies for managing acute agitation in emergency settings, challenging the stigmatizing concept of “chemical restraints” and providing practical approaches to achieve optimal patient outcomes. Did you know that many agitated patients can actively participate in medication decisions, even during a crisis?
Faculty: Scott Zeller, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: The Psychopharmacology of Agitation: Managing Behavioral Emergencies
- Pharmacologic Strategies for Managing Agitation: General Recommendations and Treatments Goals
In this episode, we explore how famotidine, a common heartburn medication, might help treat post-COVID brain fog. New research suggests this H2 blocker could improve cognitive function in recovering patients. But how does a stomach acid reducer potentially clear mental haziness?
Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 62
- Famotidine for COVID-19 Brain Fog: A Promising Treatment Option
In this episode, we explore nonpharmacologic strategies for managing agitated patients, focusing on verbal de-escalation techniques. Did you know that using physical restraints adds an average of four hours to an emergency department stay? Dr. Scott Zeller shares evidence-based approaches to transform crisis intervention in emergency settings.
Faculty: Scott Zeller, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: The Psychopharmacology of Agitation: Managing Behavioral Emergencies
- Nonpharmacologic Strategies for Managing Agitation: Verbal De-Escalation
In this episode, we explore the RADAR trial's findings on antipsychotic dose reduction in schizophrenia. Can patients with chronic schizophrenia safely reduce or discontinue their antipsychotic medications without increasing relapse risk? The trial's results challenge common assumptions about medication reduction and provide crucial guidance for clinical practice.
Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CME: Quick Take Vol. 62
- Antipsychotic Dose Reduction in Schizophrenia: Insights From the RADAR Trial
In this episode, we explore the challenges of diagnosing and managing agitation in emergency settings, focusing on mood disorders and substance use. Dr. Scott Zeller shares insights on differentiating acute mania from substance-induced psychosis. How can clinicians navigate the complex interplay between psychiatric symptoms and substance effects in emergencies?
Faculty: Scott Zeller, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: The Psychopharmacology of Agitation: Managing Behavioral Emergencies
- Other Psychiatric Diagnoses in Agitated Patients: Mood and Substance Use Disorders
In this episode, we explore the use of high-dose olanzapine as a potential alternative to clozapine for treatment-resistant schizophrenia. We discuss a systematic review that examines the efficacy and safety of olanzapine doses above the FDA-approved maximum. Could high-dose olanzapine be a viable option when patients refuse clozapine?
Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 61
- Is High-Dose Olanzapine an Option for Treatment-Resistant Schizophrenia?
In this episode, we explore how integrating psychodynamic principles into pharmacotherapy can enhance treatment outcomes. We discuss seven key features of psychodynamic psychotherapy and their application in routine psychiatric practice. How might understanding a patient's fantasies about their illness impact their response to medication?
Faculty: David Mintz, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: Psychodynamic Psychopharmacology: Alliance, Communication, and Psychotherapy Skills
- Psychotherapy Skills in Everyday Practice: Ordinary Medical Psychotherapy
In this episode, we explore strategies for discontinuing benzodiazepines in hospitalized elderly patients. We discuss a recent Israeli study that tested two interventions during inpatient stays. Can a simple hospital-based intervention lead to successful long-term medication changes?
Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 61
- Stopping Benzodiazepines and Z-Drugs in Hospitalized Elderly Patients
In this episode, we explore the critical role of therapeutic alliance in psychopharmacology. We discuss how factors like empathy, communication, and shared decision-making can significantly impact treatment outcomes. Did you know that a doctor's warm voice can increase appointment adherence by 162%?
Faculty: David Mintz, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: Psychodynamic Psychopharmacology: Alliance, Communication, and Psychotherapy Skills
- Pharmacotherapy Alliance, Treatment Preferences, and Communication
In this episode, we explore the cardiac and metabolic safety profile of antipsychotics in youth, based on a World Health Organization Safety Database analysis. We discuss age-dependent risks, specific medication concerns, and the importance of monitoring. How can clinicians balance the benefits of antipsychotics with potential cardiometabolic risks in young patients?
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 20
- Cardiac and Metabolic Safety Profile of Antipsychotics in Youth
In this episode, we explore the unexpected consequences of promoting a purely biological view of mental illness. How does framing mental health conditions as solely biological affect stigma, patient outcomes, and physician empathy? We delve into the complex interplay between biological and psychosocial factors in mental health treatment.
Faculty: David Mintz, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: Psychodynamic Psychopharmacology: Alliance, Communication, and Psychotherapy Skills
- The Biological Theory of Illness and Stigma
In this episode, we explore the bidirectional relationship between psychiatric disorders and cardiovascular disease, discussing a groundbreaking study involving over 900,000 subjects. We ask: Can a mental health diagnosis increase your risk of heart disease?
Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership her
- Earn 0.5 CMEs: Quick Take Vol. 60
- Psychiatric Disorders and Subsequent Risk of Cardiovascular Disease
In this episode, we explore the science behind the art of psychopharmacotherapy with Dr. David Mintz. We delve into how psychosocial factors, including the prescriber's approach, can significantly impact medication outcomes. Did you know that some psychiatrists achieve better results with placebos than others do with active medications?
Faculty: David Mintz, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: Psychodynamic Psychopharmacology: Alliance, Communication, and Psychotherapy Skills
- The Science of the Art of Psychopharmacotherapy
In this episode, we explore the long-term effects of methylphenidate on sleep in children and adolescents with ADHD. Can stimulant medication actually improve sleep in ADHD patients? We dive into surprising research findings that challenge common assumptions about ADHD treatment and sleep disturbances.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 20
- Long-Term Effects of Methylphenidate on Sleep in Children and Adolescents With ADHD
In this episode, we explore the strategic use of natural medications in psychiatry, focusing on combination therapies for various mental health conditions. Dr. David Mischoulon discusses potential synergies between natural remedies and conventional drugs, as well as all-natural combinations. But how do we balance efficacy with safety when using these less-studied treatments?
Faculty: David Mischoulon, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.75 CME: Natural Medication in Psychiatry: Focus on Versatile Agents and Combination Strategies
- Potential Combinations of Natural Medication for Psychiatric Disorders
In this episode, we explore the use of memantine in treating trichotillomania and skin picking disorder. Could this common Alzheimer's medication be the breakthrough we've been waiting for in managing body-focused repetitive behaviors? Dr. Bob Hudak discusses a promising study that offers new hope for patients struggling with these often-overlooked conditions.
Faculty: Robert Hudak, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 60
- Efficacy of Memantine in Treating Trichotillomania and Skin-Picking Disorder
In this episode, we explore Ashwagandha, a versatile natural remedy in psychiatry. We discuss its potential applications in treating anxiety, depression, OCD, and other mental health disorders. Could this ancient herb be the key to managing treatment-resistant patients?
Faculty: David Mischoulon, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.75 CME: Natural Medication in Psychiatry: Focus on Versatile Agents and Combination Strategies
- Ashwagandha (ASW): Potential Indications and Administration in Psychiatric Disorders
In this episode, we explore the controversial use of electroconvulsive therapy (ECT) in adolescents with severe depression and suicidality. We discuss a study examining ECT's effectiveness, factors influencing outcomes, and its potential as a treatment option. Is ECT a viable last resort for treatment-resistant depression in teens?
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 19
- Electroconvulsive Therapy for Adolescents With Severe Depression and Suicidality
In this episode, we explore the potential uses of Cannabidiol (CBD) in psychiatric practice. We discuss its mechanisms, evidence for various disorders, and guidelines for safe use. Is CBD the next breakthrough in mental health treatment, or just another passing trend?
Faculty: David Mischoulon, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.75 CME: Natural Medication in Psychiatry: Focus on Versatile Agents and Combination Strategies
- Cannabidiol: Evidence for Psychiatric Disorders and Recommendations for Using It
In this episode, we explore the use of medical cannabis in treating Parkinson's disease. We discuss a retrospective study that reveals promising results for both motor and non-motor symptoms. Could medical cannabis be the versatile solution we've been seeking for Parkinson's treatment?
Faculty: Gregory Pontone, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 59
- Medical Cannabis in the Treatment of Parkinson’s Disease
In this episode, we explore the potential of N-acetylcysteine (NAC) in treating mood disorders. We discuss its mechanism of action, clinical evidence for its use in depression and bipolar disorder, and its possible benefits for both adults and children. Could this natural compound revolutionize our approach to mood stabilization?
Faculty: David Mischoulon, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.75 CME: Natural Medication in Psychiatry: Focus on Versatile Agents and Combination Strategies
- Exploring the Evidence of N-Acetyl-Cysteine (NAC) for Mood Disorders
In this episode, we explore the potential use of probiotics in treating ADHD symptoms in children and adolescents. Could the gut microbiome hold the key to managing this complex neurodevelopmental disorder? We discuss a recent meta-analysis and its implications for future research and clinical practice.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 19
- Efficacy of Probiotics in Treating ADHD Symptoms
In this episode, we explore the challenges and best practices for managing bipolar disorder during pregnancy. We discuss key medications, their risks and benefits, and the importance of individualized treatment plans. How do we balance maternal mental health with fetal safety when treating bipolar disorder in pregnant women?
Faculty: Vivien Burt, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: Perinatal Treatment of Bipolar Disorder
- Guiding Principles for Treating Bipolar Disorder During Pregnancy
In this episode, we explore a recent study challenging the safety concerns surrounding haloperidol use in older patients post-surgery. We discuss its implications for managing delirium and compare it to other antipsychotics. Could haloperidol be the unsung hero in our psychopharmacological arsenal?
Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 59
- Comparative Safety of Oral Antipsychotics for Adverse Events in Adults After Surgery
In this episode, we explore the use of atypical antipsychotics during pregnancy for women with bipolar disorder. We discuss recent research findings, potential risks, and the delicate balance between managing maternal mental health and fetal safety. How do clinicians approach this challenging clinical decision?
Faculty: Vivien Burt, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: Perinatal Treatment of Bipolar Disorder
- Risks of Using Antipsychotics During Pregnancy
In this episode, we explore the use of risperidone in treating anorexia nervosa in children and adolescents. We discuss a groundbreaking study examining its efficacy and tolerability. Can atypical antipsychotics like risperidone offer hope for young anorexia patients, or are we still searching for effective pharmacological treatments?
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CME: CAP Smart Takes Vol. 18
- Efficacy of Risperidone as Treatment for Anorexia Nervosa
In this episode, we explore the complexities of managing lithium during pregnancy for women with bipolar disorder. How do lithium levels change throughout pregnancy, and what monitoring is necessary? We discuss dosing strategies, fetal monitoring, and postpartum considerations to ensure the best outcomes for both mother and baby.
Faculty: Vivien Burt, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: Perinatal Treatment of Bipolar Disorder
- Bipolar Disorder During Pregnancy: Management of Lithium
In this episode, we explore the revolutionary potential of daridorexant, a new dual orexin receptor antagonist (DORA) for treating chronic insomnia. We discuss its unique mechanism of action, efficacy, and implications for future insomnia treatment. Could this medication be the key to "turning off" wakefulness in stubborn cases of insomnia?
Faculty: Carlos H. Schenck, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 58
- Use of Daridorexant for the Management of Chronic Insomnia
In this episode, we explore the risks and benefits of using lithium during pregnancy for women with bipolar disorder. We discuss recent research on cardiac malformations and dose-dependent risks. Is the fear of lithium use in pregnancy justified by the latest evidence?
Faculty: Vivien Burt, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: Perinatal Treatment of Bipolar Disorder
- Risks of Using Lithium in Pregnancy
In this episode, we explore a groundbreaking study on escitalopram's efficacy in treating generalized anxiety disorder in children and adolescents. We discuss its potential as the first FDA-approved medication for youth anxiety. How might this change our approach to pediatric anxiety treatment?
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 18
- The Role of Escitalopram in Treating Generalized Anxiety Disorder in Youth
In this episode, we explore psychodynamic psychopharmacology and its role in addressing treatment-resistant cases. We discuss how patient-doctor relationships, transference, and countertransference can impact medication effectiveness. How might your own unconscious biases influence your prescribing decisions?
Faculty: David Mintz, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.75 CME: Psychodynamic Psychopharmacology: From Biomedical Approaches to Patient Relationships
- Cultivating a Therapeutic Alliance
In this episode, we explore the therapeutic potential of psychedelic compounds in psychiatry. We discuss their definition, mechanism of action, and potential uses in treating anxiety and depression. How might psychedelics reshape the future of psychopharmacology?
Faculty: Sidney LeFay, D.O. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 58
- Psychedelics as Transformative Therapeutics
In this episode, we explore the concept of patient ambivalence in psychopharmacology. How can understanding a patient's conflicting feelings about treatment improve outcomes? We discuss strategies for recognizing and addressing ambivalence, and its impact on medication adherence and effectiveness.
Faculty: David Mintz, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.75 CME: Psychodynamic Psychopharmacology: From Biomedical Approaches to Patient Relationships
- Attending the Patient’s Ambivalence
In this episode, we explore vaping cessation methods used by US adolescent e-cigarette users. We discuss a study analyzing the prevalence and effectiveness of various quitting strategies, considering factors like demographics and perception of harm. How can healthcare providers tailor their approach to help teens quit vaping?
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 17
- Adoption of Vaping Cessation Methods by U.S. Adolescents
In this episode, we explore Psychodynamic Psychopharmacology, an innovative approach to treating medication-resistant patients. We discuss how psychological factors influence drug responses and learn techniques to enhance treatment outcomes. Could understanding the meaning patients attach to their medications be the key to unlocking treatment resistance?
Faculty: David Mintz, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.75 CME: Psychodynamic Psychopharmacology: From Biomedical Approaches to Patient Relationships
- An Introduction to Psychodynamic Psychopharmacology
In this episode, we explore the complex relationship between benzodiazepine use and suicide risk, examining a groundbreaking French study that challenges our understanding of this connection. Is our go-to anxiety treatment potentially increasing suicide risk?
Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 57
- Risk for Suicide Attempts and Suicide Associated With Benzodiazepines
In this episode, we explore how a psychodynamic approach can shed light on treatment-resistant cases. Can understanding a patient's psychological dynamics be the key to unlocking better outcomes?
Faculty: David Mintz, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.75 CME: Psychodynamic Psychopharmacology: From Biomedical Approaches to Patient Relationships
- Understanding the Problem of Treatment Resistance
In this episode, we explore the fascinating connection between ADHD, pain sensitivity, and methylphenidate treatment in children. Could methylphenidate help reduce pain sensitivity in pediatric ADHD patients?
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 17
- Effect of Methylphenidate on Pain Perception Thresholds in Children With ADHD
In this episode, we dive into the complex world of treating insomnia in patients with major depressive disorder. What's the best approach to help these patients find restful sleep and improve their mood? Join us as we explore a range of strategies, from medication to behavioral interventions.
Faculty: Amit Chopra, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Navigating Insomnia in Major Depressive Disorder: Advances in Management
- Treatment Strategies for Managing Insomnia in MDD
In this episode, we explore the latest pharmacologic interventions for managing insomnia in patients with major depressive disorder. Can dual orexin receptor antagonists, melatonin agonists, and low-dose doxepin provide relief for those struggling with sleep? Join us as we discuss the advances in treating insomnia and depression.
Faculty: Amit Chopra, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CMEs: Navigating Insomnia in Major Depressive Disorder: Advances in Management
- Other Pharmacologic Interventions for Insomnia
In this episode, we explore the potential of fish oil as an adjunct to cognitive–behavioral therapy for treating depression in youth. Can this combination enhance treatment outcomes, or is cognitive–behavioral therapy alone just as effective? Join us as we dive into this intriguing study.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 16
- Is Fish Oil Effective in Youth Depression?
In this episode, we explore the use of benzodiazepines and nonbenzodiazepine hypnotics for managing insomnia in major depressive disorder. How do these medications work, and what are the key considerations when prescribing them? Join us as we navigate the complexities of pharmacologic interventions for insomnia.
Faculty: Amit Chopra, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Navigating Insomnia in Major Depressive Disorder: Advances in Management
- Pharmacologic Interventions for Insomnia: Benzodiazepines and Non-Benzodiazepine Hypnotics
In this episode, we explore the safety of antipsychotics in patients with liver disease. How can psychiatrists navigate the risk–benefit balance when treating medically complex individuals? Dr. Sydney LeFay discusses key insights from a recent review article, guiding antipsychotic selection and monitoring.
Faculty: Sydney LeFay, D.O. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.75 CMEs: Quick Take Vol. 56
- Antipsychotic Safety in Liver Disease
In this episode, we explore the complex relationship between insomnia and major depressive disorder. How does insomnia impact the course and treatment of depression? Join us as we dive into the neurobiology and clinical implications of this fascinating topic with expert Dr. Amit Chopra.
Faculty: Amit Chopra, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Navigating Insomnia in Major Depressive Disorder: Advances in Management
- Understanding the Relationship Between Insomnia Disorder and MDD
In this episode, we explore the long-term effects of ADHD medication use during pregnancy on children's development. Can continuing treatment pose risks, or is it safer than previously thought? Join us as we dive into a groundbreaking Danish study that sheds light on this critical question.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 16
- In Utero Exposure to ADHD Medication and Long-Term Offspring Outcomes
In this episode, we explore the growing evidence for nonpharmacologic therapies in managing fibromyalgia symptoms. Could a combination of exercise, cognitive–behavioral therapy, and integrative approaches, like acupuncture or yoga, be the key to better outcomes for patients resistant to traditional treatments?
Faculty: Daniel Clauw, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.75 CME: Nociplastic Pain Syndromes: Focus on Fibromyalgia
- Nonpharmacologic Therapies for Fibromyalgia
In this episode, the editorial team of the Psychopharmacology Institute discusses 3 important topics presented at the APA Annual Meeting: Prescribing psychiatric medications during pregnancy, recent advances in clozapine treatment, and managing eating disorders, namely anorexia nervosa and bulimia nervosa. The episode covers the safety and dose adjustments for medications like SSRIs, lamotrigine, and lithium during pregnancy; early initiation and monitoring of clozapine; and effective treatments, including psychotherapy, olanzapine, and fluoxetine for eating disorders.
Hosts: Flavio Guzman, M.D., Paz Badia, M.D., and Lorena Rodriguez, M.D.
In this episode, we discuss a new study on maternal depression, antidepressant use, and pregnancy complications. Can antidepressants during pregnancy harm the baby? Dr. Lauren Osborne helps us weigh the risks and benefits.
Faculty: Lauren Osborne, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 56
- Neonatal and Pregnancy Complications Following Maternal Depression or Antidepressant Exposure
In this episode, we explore the most effective pharmacologic treatments for fibromyalgia, a complex nociplastic pain syndrome. Dr. Daniel Clauw shares his insights on the top drug classes for managing fibromyalgia and discusses why opioids should be avoided. Could the hyperactive endogenous opioid system in fibromyalgia patients explain the ineffectiveness of opioids?
Faculty: Daniel Claw, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.75 CME: Nociplastic Pain Syndromes: Focus on Fibromyalgia
- Pharmacologic Therapies for Fibromyalgia
In this episode, we explore the use of antipsychotic medication in treating children and adolescents with anorexia nervosa. Can these medications play a role in promoting weight gain and reducing comorbid symptoms? Or do the risks outweigh the potential benefits in this vulnerable population?
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CME: CAP Smart Takes Vol. 15
- Antipsychotics in the Treatment of Youth With Anorexia Nervosa
In this episode, we dive into the diagnosis of fibromyalgia, a common nociplastic pain syndrome. We explore how to assess widespread pain and associated symptoms and how to understand fibromyalgia as a spectrum rather than a binary diagnosis. How can this nuanced approach help us tailor treatment strategies?
Faculty: Daniel Clauw, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.75 CME: Nociplastic Pain Syndromes: Focus on Fibromyalgia
- Diagnosing Fibromyalgia
In this episode, we delve into the potential for irreversible sexual dysfunction after SSRI use, based on a large-scale Israeli study. Could a few months or even days of antidepressant treatment lead to permanent erectile issues?
Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 55
- Risk of Irreversible Post‑SSRI Sexual Dysfunction With Antidepressants
In this episode, we discuss the management of common adverse effects associated with clozapine treatment, including myocarditis, cardiomyopathy, tachycardia, orthostatic hypotension, and metabolic syndrome. How can clinicians mitigate these risks while optimizing treatment outcomes for patients with treatment-resistant schizophrenia? Faculty: Brian Miller, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Clozapine: Management and Challenges
- Managing Cardiac and Metabolic Adverse Effects of Clozapine
In this episode, we explore relapse prevention strategies for youth with depression and anxiety disorders. Are there effective ways to reduce the risk and prolong the time to relapse? Dr. David Rosenberg discusses the findings of a recent meta-analysis and systematic review on this crucial topic.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 15
- Relapse Prevention Strategies for Depression and Anxiety in Remitted Youth
In this episode, we navigate the complexities of initiating and optimizing clozapine treatment for patients with treatment-resistant schizophrenia. How do you chart the course for successful clozapine therapy while managing side effects and drug interactions? Join us as Dr. Brian Miller shares his expertise and valuable psychopharmacology pearls.
Faculty: Brian Miller, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CMEs: Clozapine: Management and Challenges
- Initiating and Optimizing Clozapine
In this episode, we discuss the prevalence of smoking among people with psychosis, based on recent findings from the PATH study. Dr. Oliver Freudenreich shares insights on how clinicians can prioritize smoking cessation in this population. How can we bridge the health outcome disparities faced by our patients with psychosis?
Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.75 CMEs: Quick Take Vol. 55
- Tobacco Use, Nicotine Dependence, and Cessation Among Adults with Psychosis
In this episode, we delve into the use of clozapine for treatment-resistant psychosis and mood disorders. When should clinicians consider clozapine, and what do expert guidelines recommend? Dr. Brian Miller guides us through the evidence and best practices for utilizing this powerful but often underused medication.
Faculty: Brian Miller, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Clozapine: Management and Challenges
- Using Clozapine for Treatment-Resistant Psychosis and Mood Disorders
In this episode, we explore the role of lithium in treating pediatric bipolar disorder and conduct disorder. Is lithium a viable option for managing these complex conditions in children and adolescents, or are other medications more effective?
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 14
- Use of Lithium in Pediatric Bipolar Disorders and Externalizing Childhood-Related Disorders
In this episode, we explore real-world clinical cases demonstrating how broad-spectrum micronutrients can complement existing interventions for ADHD, emotional dysregulation, and mood instability. Can close monitoring and expert guidance optimize the integration of nutritional supplementation with pharmacologic treatments to create a harmonious, personalized approach?
Faculty: Amelia Villagomez, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.75 CMEs: Broad-Spectrum Micronutrients (BSMs) for Mental Health: What You Need to Know for Clinical Use
- Clinical Cases
In this episode, we discuss the groundbreaking FDA approval of zuranolone, the first oral medication specifically targeting postpartum depression. Could zuranolone's novel mechanism of action as an allopregnanolone agonist herald a new era of rapid-onset, targeted treatments for this debilitating condition affecting 1 in 8 new mothers?
Faculty: Vivien Burt, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.75 CMEs: Quick Take Vol. 54
- Zuranolone for the Treatment of Postpartum Depression
In this episode, we explore practical clinical tips for using broad-spectrum micronutrient supplements to treat mental health conditions. Can an individual's nutritional needs surpass population standards?
Faculty: Amelia Villagomez, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.75 CME: Broad-Spectrum Micronutrients (BSMs) for Mental Health: What You Need to Know for Clinical Use
- Practical Tips for Using BSMs in the Clinical Practice
In this episode, we examine whether first-trimester exposure to the antipsychotic olanzapine increases the risk of major fetal malformations. Does stopping medication abruptly also carry risks?
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 14
- Risk of Major Malformations Following First-Trimester Exposure to Olanzapine
In this episode, we delve into the safety considerations of using broad-spectrum micronutrient formulas in mental disorder treatment, mainly how these supplements can interact with other medications. Is it safe to use these formulas alongside anesthesia during surgery?
Faculty: Amelia Villagomez, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.75 CME: Broad-Spectrum Micronutrients (BSMs) for Mental Health: What You Need to Know for Clinical Use
- BSMs and Drug Interactions
In this episode, we explore the potential of NSAIDs in delirium prevention. However, NSAIDs come with risks, such as GI bleeding or kidney injury. Can NSAIDs really help prevent delirium, and if so, how?
Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.75 CMEs: Quick Take Vol. 54
- Use of NSAIDs for Delirium Risk Reduction
In this episode, we explore the unconventional yet promising treatment modality of using broad-spectrum micronutrient formulas in mental health care. We discuss the research and clinical trials that have been undertaken to test combinations of vitamins and minerals, focusing on their safety and efficacy. What are the potential side effects of using broad-spectrum micronutrient formulas?
Faculty: Amelia Villagomez, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.75 CME: Broad-Spectrum Micronutrients (BSMs) for Mental Health: What You Need to Know for Clinical Use
- BSMs: Safety and Tolerability
In this episode, we discuss an insightful study by Strawn et al. that utilized a mega-analysis approach, combining data on over 900 MDD patients across lifespan treatment trials to elucidate differences in antidepressant treatment outcomes based on patient age. Does antidepressant efficacy differ across developmental stages—children, adolescents, and adults?
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 13
- Age's Impact on Antidepressant Response
What are some common signs that suggest a cancer patient may be developing delirium? In this episode, we explore the complex issue of delirium in advanced cancer patients. We discuss important considerations regarding medication management, the importance of distinguishing terminal from reversible delirium, and the role of antipsychotics and benzodiazepines in treatment.
Faculty: Jaroslava Salman, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Depression, Anxiety, and Delirium in Patients With Cancer
- Management of Delirium in Patients With Cancer
In this episode, we discuss the treatment of agranulocytosis or neutropenia in patients on clozapine therapy, a rare yet serious scenario that clinicians may encounter. We delve into the possibility of rechallenging clozapine treatment after such an event and explore the use of colony-stimulating factors. What's the likelihood of agranulocytosis while prescribing clozapine long term?
Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 53
- The Impact of Colony-Stimulating Factor on Clozapine Rechallenge Outcomes
In this episode, we delve into the management of anxiety in cancer patients, including the effective psychotherapeutic interventions and pharmacologic options for treating anxiety in this vulnerable group. The episode also touches on the importance of cultural sensitivity and patient education when managing anxiety in cancer patients.
Faculty: Jaroslava Salman, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Depression, Anxiety, and Delirium in Patients With Cancer
- Treating Anxiety Disorders in Patients With Cancer
In this podcast episode, Dr. David Rosenberg explores practical strategies to asess and manage common antidepressant side effects in the pediatric population. Get useful takeaways regarding activation, insomnia, withdrawal symptoms, and more.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 13
- Managing Adverse Effects of Antidepressants in Youth
In this podcast episode, Jaroslava Salman, M.D., discusses the treatment options for depressed patients with cancer. Stay a step ahead in your practice with practical tips on which psychotherapies are helpful, which antidepressants to use and for how long, what to be mindful of, and even insights into prescribing stimulants.
Faculty: Jaroslava Salman, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Depression, Anxiety, and Delirium in Patients With Cancer
- Treating Depressive Disorders in Patients With Cancer
In this podcast episode, Dr. Vivien Burt delves into a study on brexanolone for women with postpartum depression, anxiety, and insomnia. Listen in and find out the effect and time frame of brexanolone on these symptoms.
Faculty: Vivien Burt, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 53
- Effect of Brexanolone on Postpartum Depressive Symptoms, Anxiety, and Insomnia
In this podcast, Dr. David Rosenberg offers practical insights into treatment optimization for youth with tic disorders. Listen in and find out which treatment modality takes precedence, which factors need to be considered, how long to use medication, and more.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.5 CMEs: Tic Disorders in Children and Adolescents
- Treatment Optimization for Tic Disorders
In this podcast, Dr. David Rosenberg expertly addresses the questions on what to do when your adolescent patient has ADHD but uses cannabis. Should you prescribe stiimulants or not? And what if they just want stimulants for better test scores? What do you do? Listen in as Dr. Rosenberg offers useful takeaways to help you with these (all too common) dilemmas.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 12
- Prescribing Stimulants for Youth With ADHD and Co-Occurring Cannabis Use
In this podcast, Dr. David Rosenberg delves into tic disorders and psychiatric comorbidities in youth. This includes ADHD, OCD, anxiety and depression, and disruptive behaviors. Jump in and listen to practical treatment options for these cases, and stay one step ahead in your clinical practice.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.5 CME: Tic Disorders in Children and Adolescents
- Tic Disorders and Psychiatric Comorbidities
CANMAT presents a spectrum approach to mixed states. In this podcast, Dr. Jim Phelps delves into this and the DSM-5 approach, where mixed states became a specifier that can be added to a diagnosis of unipolar depression, effectively creating a spectrum approach to the diagnosis of mixed mood disorders. So, what’s a clinician to do treatment-wise? Should we or should we not use antidepressants when 4 specific symptoms are present? Find the answer to these and other questions in this podcast.
Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 52
- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) Recommendations for the Management of Patients With Bipolar Disorder With Mixed Presentations
In this podcast episode, Dr. David Rosenberg provides a much-needed understanding of tic disorders in children and adolescents. Listen in to learn what a typical course of this disorder could look like, why you may not need to substitute methylphenidate in these patients, what happens when patients supress tics, and much more.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.5 CME: Tic Disorders in Children and Adolescents
- Understanding Tic Disorders
In this podcast, Dr. David Rosenberg explores a review on metformin for youth on SGAs. Is it effective in mitigating weight gain in this population? And more importantly, should you prescribe it ASAP? Listen in as Dr. Rosenberg answers these questions and others.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 12
- Metformin for Weight Gain in Youth on Atypical Antipsychotics
In this podcast, Dr. Jim Phelps discusses the issue of diagnosing bipolar disorder within the framework of a mood spectrum. How bipolar should a patient be before switching treatment strategies? Listen in for tips and practical takeaways to answer this question and guide decision making.
Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 52
- “Cade’s Disease” and Beyond: Misdiagnosis, Antidepressant Use, and a Proposed Definition for Bipolar Spectrum Disorder
In this podcast, Dr. Schenck discusses zolpidem-induced sleeping disorder and eating disorder. Listen and find out important tips and considerations, such as this being more common in females, alerting bed partners, being careful with zolpidem doses over 10 mg, and more.
Faculty: Carlos Schenck, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.5 CME: Parasomnias Triggered by Sedative-Hypnotics: Sleepwalking and Sleep-Related Eating Disorder
- Zolpidem-Induced Sleepwalking and SRED
Cariprazine may be a good option for pediatric patients with schizophrenia and bipolar I disorder. Listen as Dr. Rosenberg summarizes study findings, which may broaden your options with children and adolescents.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 11
- Safety and Tolerability of Cariprazine in Pediatric Patients
This podcast explores medication associated with sleepwalking and sleep driving, as well as recommendations for clinicians when prescribing them to patients.
Faculty: Carlos Schenck, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.5 CME: Parasomnias Triggered by Sedative-Hypnotics: Sleepwalking and Sleep-Related Eating Disorder
- Medication-Induced SRED, Sleepwalking, and Sleepdriving
In this episode, we explore whether the olanzapine–samidorphan combination helps with psychosis while halting weight gain. We also look into the cost vs benefit of the combination as well as the metabolic side effects.
Faculty: James Phelps, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 51
- Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson’s Disease Psychosis: Systematic Review and Network Meta-Analysis
Can melatonin reduce the risk of suicidality, bodily injuries, falls, and accidents in children and adolescents? In this episode, we explore a study that delves into this question. Discover how sleep disturbances impact young individuals' health, development, cognitive skills, emotional regulation, and behavior.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 11
- Melatonin Use and the Risk of Self-Harm and Unintentional Injuries in Youth
Do you know what sleep-related eating disorder (SRED) is and how it intertwines sleep and eating pathologically? In this episode, we delve into an in-depth analysis of SRED, elucidating its diagnostic criteria, key characteristics of the diagnosis, and some intriguing aspects related to this disorder.
Faculty: Carlos Schenck, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.5 CME: Parasomnias Triggered by Sedative-Hypnotics: Sleepwalking and Sleep Related Eating Disorder
- Diagnosing Sleep-Related Eating Disorder (SRED)
This episode explores the controversial role of pimavanserin in treating psychosis in Parkinson's disease. How does it compare with quetiapine or clozapine? Sneak peek: All of these medications are effective, yet none distinctly surpasses the others.
Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 51
- Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson’s Disease Psychosis: Systematic Review and Network Meta-Analysis
Pediatric bipolar disorder treatment has evolved significantly since 2005, moving beyond lithium to several FDA-approved treatments. However, the challenges remain: How do we choose the first-line treatment? How can we mitigate and monitor side effects? In this episode, we discuss the latest practice treatment algorithms for pediatric bipolar disorder.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 10
- Psychopharmacologic Treatment Algorithms for Bipolar Disorder in Youth
Can pharmacogenomic testing improve the selection and dosing of antidepressants in patients with MDD? In this episode, we explore the findings of the PRIME Care trial and discuss the clinical significance of these tests.
Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 49
- Effect of Pharmacogenomic Testing for Drug–Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial
In this episode, we discuss the role of broad-spectrum micronutrients (BSMs) in managing symptoms of ADHD. We examine the rationale behind opting for alternative therapies for this condition and dissect the outcomes of an RCT involving BSMs for ADHD. Could micronutrients provide a comprehensive strategy for treating ADHD, thereby enhancing overall mental wellness?
Faculty: Amelia Villagomez, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.75 CME: Broad-Spectrum Micronutrients (BSM) for Mental Health: Context for Considering Micronutrient Treatment
- An Overview of Standard Treatment vs CAM for ADHD
Are you aware that a staggering 80% of ADHD patients report at least 1 side effect from their medication? In this episode, we discuss an analysis that seeks to answer an essential question: Can we predict medication nonadherence in adolescents and young adults with ADHD based on specific side effects?
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 10
- Reported Side Effects Associated With Medication Nonadherence Among Youth With ADHD
Did you know that your genes could affect how your brain processes vital nutrients? In this episode, we delve into fascinating research on micronutrient supplementation for mental disorders, such as ADHD. Discover how our genetic makeup might dictate our nutrient needs and how this can influence mental health outcomes.
Faculty: Amelia Villagomez, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.75 CME: Broad-Spectrum Micronutrients (BSM) for Mental Health: Context for Considering Micronutrient Treatment
- Rationale for Micronutrient Supplementation in Mental Illness
Could antipsychotic switching impact substance use in schizophrenia? In this episode, Dr. Jim Phelps explores the impact of antipsychotics on patients with schizophrenia and substance use disorder. He includes insights from national cohorts and clinical cases and delves into the potential effects of changing from risperidone to clozapine.
Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 49
- Associations Between Antipsychotic Use, Substance Use, and Relapse Risk in Patients with Schizophrenia: Real-World Evidence From 2 National Cohorts
Dive into the fascinating world of nutrition's impact on mental health in our latest episode. We explore intriguing studies on the Mediterranean diet's potential to alleviate depressive symptoms. Can a shift in dietary habits truly improve mental health?
Faculty: Amelia Villagomez, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.75 CME: Broad-Spectrum Micronutrients (BSM) for Mental Health: Context for Considering Micronutrient Treatment
- Depression and Mediterranean-Style Diet
In this episode, we explore a pressing problem in pediatric psychiatry: The disparities in the use of pharmacologic restraints. How can we address these biases in our healthcare system? What role do behavioral interventions play in reducing the need for these measures?
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 09
- Disparities in Pharmacologic Restraint Use in Pediatric Emergency Departments
In this episode, we discuss the causes of clozapine-induced orthostasis. Although some patients may develop tolerance, it can limit titration and potentially obstruct patients from reaching the plasma level where they respond well to the medication. There are practical management strategies for orthostasis, including slow titration based on patient complaints and encouraging fluid intake, among others.
Faculty: Jonathan Meyer, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Managing Some Unique Nonhematologic Adverse Effects of Clozapine
- Managing Clozapine-Related Orthostasis
In this episode, we discuss the potential of lavender extract, Silexan, as an alternative treatment for anxiety and insomnia with Dr. Jim Phelps. Is it truly a promising solution free from dependency and withdrawal symptoms or just an effective placebo?
Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 48
- Effect of Anxiolytic Drug Silexan on Sleep – A Narrative Review
In this episode, we explore a common yet severe side effect of clozapine: Constipation. Why does this drug cause such drastic changes in colonic transit times, and how can we manage it effectively?
Faculty: Jonathan Meyer, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Managing Some Unique Nonhematologic Adverse Effects of Clozapine
- Managing Clozapine-Related Constipation
In this episode, we discuss a comprehensive study on the potential cardiovascular risks of ADHD medication. Although these medications pose minimal risk for those without preexisting conditions, there seems to be an elevated risk for those with preexisting cardiovascular diseases. Should we confidently prescribe these medications?
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about Silver and Gold memberships here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 09
- Risk of Cardiovascular Diseases Associated With Medications Used in ADHD
In this episode, we delve into the problem of sialorrhea or excessive salivation in patients on clozapine. Why does this occur, and how can it be managed? Join us as Dr. Jonathan Meyer shares his expertise on this unique side effect.
Faculty: Jonathan Meyer, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Managing Some Unique Nonhematologic Adverse Effects of Clozapine
- Managing Clozapine-Related Sialorrhea
Can a simple lab test guide our choice of antidepressants? Explore the intriguing link between inflammation, measured by C-reactive protein (CRP) levels, and the effectiveness of certain antidepressants in this episode.
Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 48
- C-Reactive Protein Could Predict the Efficacy of SSRIs in Clinical Practice: A Cohort Study of Large Samples in the Real World
Could ketamine be the breakthrough we need in treating adolescent depression? Join us in this episode as we explore the potential of ketamine therapy and its rapid antidepressant effects. Also, learn how ketamine works, its safety profile, and why it's not quite ready for mainstream use in adolescents.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 08
- Ketamine for Adolescent Depression
In this episode, we dive into the puzzling case of a 67-year-old man experiencing violent moving nightmares. Is it rapid eye movement sleep behavior disorder, frequent and recurring nightmares, night terrors, PTSD, or another parasomnia? Tune in as we explore potential diagnoses with our expert Dr. Carlos Schenck.
Faculty: Carlos Schenck, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.75 CME: Parasomnias Triggered by Antidepressant Medications: REM SleepBehavior Disorder and Restless Legs Syndrome
- A Clinical Case and Exclusive Videos On RBD and RLS
In this episode, we delve into a new horizon in the management of acute agitation. We discuss dexmedetomidine, a drug that's been around since 1999, recently reformulated into a sublingual film and FDA approved for treating agitation associated with schizophrenia or bipolar I or II disorder. We explore the results from a recent randomized trial and its potential for transforming psychiatric care.
Faculty: Jim Phelps, M.D.
Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 47
- Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial
In this episode, we dive into rapid eye movement sleep behavior disorder (RBD). Did you know that RBD's prevalence is on par with schizophrenia in middle-aged and older adults? Tune in as we explore the prevalence, assessment, and management of RBD, a condition that is not only a sleep disorder but a potential harbinger of severe neurological conditions, like Parkinson's Disease and Dementia with Lewy Bodies.
Faculty: Carlos Schenck, M.D.
Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.75 CME: Parasomnias Triggered by Antidepressant Medications: REM Sleep Behavior Disorder and Restless Legs Syndrome
- Prevalence, Assessment, and Management of RBD
In this episode, we dive deep into the effects of ADHD medication on anxiety and depressive symptoms in children and adolescents. Can these medications significantly exacerbate symptoms of anxiety or depression? Or do these symptoms arise more from the underlying condition of ADHD? We will delve into these critical questions and more through a thorough exploration of a comprehensive meta-analysis.
Faculty: David Rosenberg, M.D.
Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 08
- Impact of ADHD Medications on Anxiety and Depression in Youth
In this episode, we delve deep into the diagnostic mysteries of RBD, the need for video polysomnography, and the mechanisms leading to RBD. Whether you are a veteran or new to the field, this episode promises to deepen your understanding of RBD.
Faculty: Carlos Schenck, M.D.
Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.75 CME: Parasomnias Triggered by Antidepressant Medications: REM Sleep Behavior Disorder and Restless Legs Syndrome
- Diagnosing REM Sleep Behavior Disorder
Are we missing a vital piece in the schizophrenia treatment puzzle? In this episode, we explore the intriguing and controversial role of N-acetylcysteine (NAC) in schizophrenia. We dive deep into the evidence, the theories, and the ongoing debates about this seemingly simple over-the-counter supplement. Could NAC be the key to unlocking better outcomes for those with schizophrenia, or is it just another dead end?
Faculty: Jim Phelps, M.D.
Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 47
- Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia
How can N-acetyl cysteine (NAC) and S-adenosyl methionine (SAMe) be effectively integrated into child and adolescent psychiatric treatment? In this episode, we dive deep into the world of NAC and SAMe and explore their potential applications, dosage, side effects, and more.
Faculty: David Rosenberg, M.D.
Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Natural Medications in Child and Adolescent Psychiatry
- Administration of N-Acetylcysteine and S-Adenosylmethionine in Children and Adolescents
How has the use of antipsychotics among children and adolescents been affected by the COVID-19 pandemic in the United States? In this episode, we delve into pandemic-induced trends in youth psychotropic prescriptions. Uncover how COVID-19 reshaped mental health services and psychopharmacology among young individuals.
Faculty: David Rosenberg, M.D.
Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 07
- Psychotropic Prescriptions in Youth During COVID-19 Pandemic
Can nature’s remedies hold the key to mental well-being in our youth? In this episode, we delve into the potential uses and limitations of St. John’s wort and valerian in child and adolescent psychiatry and, most importantly, their evidence in treating psychiatric disorders in this population.
Faculty: David Rosenberg, M.D.
Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Natural Medications in Child and Adolescent Psychiatry
- St. John’s Wort and Valerian: Potential Indications in Children and Adolescents
Have you ever pondered the mystery behind the effectiveness of different SSRI dosing strategies for premenstrual dysphoric disorder (PMDD)? In this episode, we delve deep into the complex world of PMDD treatments, focusing on the intriguing comparison between intermittent luteal phase dosing and continuous dosing of serotonergic antidepressants.
Faculty: Jim Phelps, M.D.
Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 46
- Intermittent Selective Serotonin Reuptake Inhibitors for Premenstrual Syndromes: A Systematic Review and Meta-Analysis of Randomized Trials
Have you ever wondered how natural remedies like omega-3 fatty acids might influence child and adolescent psychiatry? In this episode, we delve into the intriguing world of omega-3 fatty acids and their potential role in treating various psychiatric disorders in children and adolescents, such as major depressive disorder, bipolar disorder, ADHD, and ASD.
Faculty: David Rosenberg, M.D.
Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Natural Medications in Child and Adolescent Psychiatry
- Use of Omega-3 Fatty Acids in Children and Adolescents
Have you ever wondered about the safety and effectiveness of ADHD medications in preschoolers? In this episode, we discuss a pioneering double-blind, fixed-dose study exploring the use of lisdexamfetamine in children aged 4–5 years. We delve into the nuances of this complex topic, from the increasing trend of psychotropic medication use in young children, to the unique characteristics that distinguish lisdexamfetamine from other amphetamine medications.
Faculty: David Rosenberg, M.D.
Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 07
- Efficacy and Safety of Lisdexamfetamine in Preschool Children with ADHD
In this episode, we delve into the intriguing world of ginkgo biloba and its potential role in treating ADHD in children and adolescents. Can this ancient herbal remedy offer a valuable alternative or adjunctive therapy?
Faculty: David Rosenberg, M.D.
Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Natural Medications in Child and Adolescent Psychiatry
- Use of Ginkgo Biloba in Children and Adolescents
In this episode, we delve into the intriguing world of COVID-19's long-term effects in psychiatry. We explore a groundbreaking study that examines the duration of COVID-associated psychiatric disorders and variations in susceptibility by age. How long do these disorders persist, and are certain age groups more affected?
Faculty: Jim Phelps, M.D.
Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 46
- Neurologic and Psychiatric Risk Trajectories After SARS-CoV-2 Infection: An Analysis of 2-Year Retrospective Cohort Studies Including 1,284,437 Patients
In this episode, you'll discover the preferred second-generation antipsychotics for augmenting treatment for obsessive-compulsive disorder: Risperidone and aripiprazole. We discuss their effectiveness and important considerations when choosing between them. What factors should clinicians weigh when deciding on an augmentation strategy?
Faculty: David Osser, M.D.
Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Algorithm for the Pharmacotherapy of Obsessive-Compulsive Disorder
- Node 4: SSRI Augmentation With SGA
In this episode, we focus on the challenges faced in metabolic monitoring of youth receiving second-generation antipsychotics (SGAs), including the strategies to overcome these barriers and ensure the long-term health of young patients on SGAs.
Faculty: David Rosenberg, M.D.
Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 06
- Barriers to Metabolic Monitoring of SGAs in Youth
In this episode, we delve into the potential outcomes after the first SSRI trial for OCD. With SSRIs being a first-line treatment, understanding response patterns is crucial. What course of action should be taken when patients exhibit significant symptom improvement, partial relief, or no response? Discover when to discontinue, switch, or augment treatment.
Faculty: David Osser, M.D.
Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Algorithm for the Pharmacotherapy of Obsessive-Compulsive Disorder
- Node 2: Potential Outcomes After the First Trial
In this episode, Dr. Richard Seeber and his special guests, Dr. Lorena Rodriguez and Dr. Paz Badia, discuss the topics covered in the APA Annual Meeting 2023, from technology in mental health practice to the use of cognitive–behavioral therapy for suicide prevention. Get ready to explore topics like ECT, ADHD, women's health, and much more. How can the integration of technology revolutionize mental health practice?
Faculty: Paz Badia, M.D. and Lorena Rodríguez, M.D.
Host: Richard Seeber, M.D.
Learn more about our memberships here
In this episode, we delve into the fascinating world of microdosing psilocybin. A recent randomized trial examined the effects of microdosing using various outcome measures. Surprisingly, the acute effects were significantly more intense for the active dose but only when participants correctly identified their experimental condition.
Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 45
- Microdosing With Psilocybin Mushrooms: A Double-Blind Placebo-Controlled Study
What factors should clinicians consider when choosing an SSRI for treating patients with OCD? In this episode, we dive into the first-line treatment for OCD: SSRIs. Discover the most effective SSRIs for treating OCD, recommended doses, and potential adverse effects.
Faculty: David Osser, M.D.
Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Algorithm for the Pharmacotherapy of Obsessive-Compulsive Disorder
- Node 2: First-Line Treatment: SSRIs
Are there any particular situations where nonstimulant medications may be especially effective for ADHD? In this episode, we discuss nonstimulant treatments for ADHD. Although stimulants are commonly used for ADHD, nonstimulant options like atomoxetine, viloxazine, clonidine, and guanfacine have been FDA approved and can be equally effective in certain populations. Listen in as we share clinical pearls on how to tailor treatments for each patient's unique needs.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about Silver and Gold memberships here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 06
- Nonstimulant Treatments for ADHD
In this episode, we share insights into the comorbidities and other considerations that can impact the treatment algorithm for OCD. From the risks of medication use in pregnant women, to the challenges of treating OCD in patients with comorbid bipolar disorder, this episode provides valuable clinical pearls for clinicians looking to improve their approach to treating OCD.
Faculty: David Osser, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Algorithm for the Pharmacotherapy of Obsessive-Compulsive Disorder
- OCD Comorbidities and Other Circumstances: Variations in the Treatment Algorithm
In this episode, we discuss rapid cycling bipolar disorder and its treatment, focusing on the use of the combination of lamotrigine and lithium. We also highlight the importance of checking thyroid status and tapering antidepressants in patients with rapid cycling.
Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 45
- Lamotrigine and Lithium Combination for Treatment of Rapid Cycling Bipolar Disorder: Results From Meta-Analysis
In this episode, we discuss the potential use of melatonin as a safe and effective pharmacotherapy for sleep disturbances in children with ADHD and ASD. Did you know that up to 80% of children with ASD experience sleep disorders? Listen in to learn how melatonin can help improve sleep onset and duration in these patients. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Atypical Psychopharmacologic Strategies for Children and Adolescents
- Potential Indications of Melatonin and Secretin in Children and Adolescents
Which medications are safe and effective for treating nonsuicidal self-injury (NSSI) in children and adolescents? In this episode, we discuss the use of psychotropic medications in treating NSSI, which is becoming increasingly common in this population and can predict future suicide attempts.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 05
- Psychotropic Drugs for Treating Nonsuicidal Self‑Injury in the Youth
This episode discusses D-cycloserine’s potential indications and administration in children and adolescents, including the evidence for anxiety disorders, OCD, ASD, and PTSD. It also mentions the dosage, administration, benefits, and side effects of D-cycloserine in youth.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Atypical Psychopharmacologic Strategies for Children and Adolescents
- D-Cycloserine: Potential Indications and Administration in Children and Adolescents
Antidepressants are commonly used to treat depression, but how effective are they? In this episode, we discuss the concept of the minimal clinically important difference (MCID) and how it can be applied to assess antidepressant efficacy in treating depression. Specifically, knowing MCID estimates helps to shed light on recent controversies regarding antidepressant efficacy.
Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 44
- Estimates of the Minimal Important Difference to Evaluate the Clinical Significance of Antidepressants in the Acute Treatment of Moderate-To-Severe Depression - Part 2
What is the role of memantine in pediatric populations? This episode discusses memantine’s potential indications and administration in children and adolescents, an explanation of the theory of glutamatergic dysregulation, and the evidence of memantine for ASD, OCD, and mood disorders.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Atypical Psychopharmacologic Strategies for Children and Adolescents
- Memantine: Potential Indications in Children and Adolescents
In this episode, we examine the tolerability, safety, and effectiveness of low-dose olanzapine in adolescents with anorexia nervosa (AN). Learn about the potential benefits and risks of using olanzapine in AN patients and the importance of a multidisciplinary approach in treating this challenging population.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 05
- Low-Dose Olanzapine for Treating Adolescents With Anorexia Nervosa
In this episode, we discuss the potential uses and challenges of naltrexone in children and adolescents while addressing the limited and conflicting evidence. We also examine the dosage, side effects, and important considerations for using naltrexone in young populations.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Atypical Psychopharmacologic Strategies for Children and Adolescents
- Naltrexone: Potential Indications and Administration in Children and Adolescents
Would a slower lamotrigine titration rate decrease the likelihood of developing the dreaded lamotrigine-associated rash? This episode discusses the possible advantages of slower lamotrigine titration rates, tips for managing benign rashes, and when to rechallenge lamotrigine.
Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 44
- Impact of Selected Initial Titration Schedules on Safety and Long-Term Effectiveness of Lamotrigine for the Treatment of Mood Disorders
In this episode, we dive into a topic that's especially relevant for those working with older adults: The use of benzodiazepines and sedative-hypnotics. We explore the unique considerations of prescribing these medications to geriatric patients and the importance of deprescribing them when possible.
Faculty: Lauren Gerlach, D.O. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Updates on Geriatric Psychopharmacology
- Considerations for Using Benzodiazepines and Benzodiazepine Receptor Agonists in the Geriatric Population
In this episode, we delve into lithium's efficacy and potential long-term effects in younger patients and what clinicians should carefully monitor in this population.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 04
- Long-Term Effects of Lithium Use on Children and Adolescents
Are mood stabilizers the right choice for elderly patients? This episode discusses key insights about using mood stabilizers in the geriatric population, including side effects and monitoring for lithium, valproic acid, lamotrigine, carbamazepine, and gabapentinoids.
Faculty: Lauren Gerlach, D.O. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Updates on Geriatric Psychopharmacology
- Considerations for Using Mood Stabilizers in the Geriatric Population
Do you have a patient suffering from postpartum depression? In this episode, we discuss a new study on light therapy as a potential treatment for postpartum depression, including the response rate, adverse effects, and effects on sleep quality.
Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 43
- Efficacy of Bright Light Therapy in Perinatal Depression: A Randomized, Double-Blind, Placebo-Controlled Study
This episode discusses some strategies for starting antidepressants in the elderly, the important role of titrating doses, the efficacy of SSRIs, the side effects and drug–drug interactions of different medications, and clinical tips for using SSRIs and SNRIs in this population.
Faculty: Lauren Gerlach, D.O. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Updates on Geriatric Psychopharmacology
- Using SSRIs and SNRIs in the Geriatric Population
Is duloxetine a viable option for youth with MDD? In this episode, we discuss the need for additional medication options in youth with depression as well as an RCT of duloxetine to assess its efficacy and a label extension trial to evaluate its long-term safety.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 04
- Efficacy and Safety of Duloxetine in Children and Adolescents With MDD in Japan
What are the most common challenges when prescribing psychotropics to older adults? This episode discusses the challenges in prescribing psychotropics to the geriatric population, such as poor medication adherence and the risks of inappropriate prescribing. It also introduces a clinical case and emphasizes the importance of medication reconciliation.
Faculty: Lauren Gerlach, D.O. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.25 CME: Updates on Geriatric Psychopharmacology
- Challenges in Prescribing Psychotropics in the Geriatric Population and Mrs. M’s Case
In this episode, we discuss an updated review of 11 studies that seek to evaluate the effect of antidepressants on the risk of hip and vertebral bone fractures. Although the overall effect size seems large, the absolute risk increase might be small.
Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 43
- Antidepressants and Vertebral and Hip Risk Fracture: An Updated Systematic Review and Meta-Analysis
Are antidepressants effective for managing explosive behavior? In this episode, we discuss the efficacy of antidepressants and mood stabilizers for managing explosive behavior, including some proposed doses of lithium and divalproex sodium, and the indications for using antidepressants.
Faculty: Carrie Vaudreuil, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.75 CME: Managing Explosive Behavior in Children and Adolescents
- Antidepressants and Mood Stabilizers for Managing Explosive Behavior
In this episode, we discuss a meta-analysis that included 6 million patients to assess whether pharmacotherapy increases the risk of substance use or misuse, specifically the risk of using stimulant medications in children with ADHD.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Smart Takes Vol. 03
- Impact of Pharmacotherapy of Childhood-Onset Psychiatric Disorders on the Development of Substance Use Disorders
In this episode, we discuss the SGAs with the most evidence for explosive behavior, their side effects, and monitoring recommendations. We also address the reasons for considering other SGAs and clarify which FGA has the most evidence for aggression.
Faculty: Carrie Vaudreuil, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.75 CME: Managing Explosive Behavior in Children and Adolescents
- First- and Second-Generation Antipsychotics for Managing Explosive Behavior
Should we start prescribing metformin to our patients on clozapine? In this episode, we discuss several articles on the efficacy of clozapine in preventing clozapine-induced weight gain, including some evidence on when metformin is more effective.
Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 42
- Metformin for the Prevention of Clozapine-Induced Weight Gain: A Retrospective Naturalistic Cohort Study
In this episode, we discuss the management of acute aggression in children and adolescents, including therapeutic support for explosive behavior, psychosocial crisis management techniques, and the medications used for acute aggression.
Faculty: Carrie Vaudreuil, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.75 CME: Managing Explosive Behavior in Children and Adolescents
- Management of Acute Aggression in Children and Adolescents
In this episode, we discuss whether early nonresponse in adolescents with first-episode psychosis predicts longer-term nonresponse and nonremission. We also explain when it is most likely that symptom improvement occurs and some other considerations when there is nonresponse.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: CAP Smart Takes Vol. 03
- Early Antipsychotic Nonresponse as a Predictor of Nonresponse in Adolescents With Psychosis
In this episode, we discuss the differential diagnosis of explosive behavior in children and adolescents, including the differences in these behaviors when they are associated with mood or anxiety disorders and disruptive behavior disorders.
Faculty: Carrie Vaudreuil, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.75 CME: Managing Explosive Behavior in Children and Adolescents
- Management of Acute Aggression in Children and Adolescents
In this episode, we discuss the long-term follow-up of psychosis and schizophrenia in children and adolescents, including predictors of poor long-term outcomes and the comorbidities associated with schizophrenia in adults.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.5 CME: Publication Title
- Long-Term Follow-Up of Psychosis and Schizophrenia in Children and Adolescents
In this episode, we discuss a recent systematic umbrella review of the evidence behind the serotonin theory of depression and the controversy this review has generated. We explore the evidence presented regarding the interplay between serotonin and depression and present concrete steps to address several concerns generated by the review.
Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 42
- The Serotonin Theory of Depression: A Systematic Umbrella Review of the Evidence
Is there an association between SSRIs and type 2 diabetes in children and adolescents? In this episode, we discuss whether there is an association. We also explain whether there is an intraclass risk among different SSRIs.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Smart Take Vol. 02
- SSRIs and Risk of Type 2 Diabetes in Children and Adolescents
In this episode, we discuss additional clinical tips for treating schizophrenia in children and adolescents, including the considerations for selecting antipsychotics, recommendations for nonresponse, and when to use clozapine.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1.5 CME: Psychosis and Schizophrenia in Children and Adolescents
- Additional Clinical Tips for Treating Schizophrenia In Children and Adolescents
In this episode, we review the current literature on the association between exercise and the risk for depression. Specifically, how much physical activity is associated with a lower risk for depression? We also discuss the World Health Organization recommendations for the ideal range of physical activity.
Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Quick Take Vol. 41
- Association Between Physical Activity and Risk of Depression: A Systematic Review and Meta-Analysis
In this episode, we discuss treatment options for managing psychosis and schizophrenia in children and adolescents, including the FDA-approved antipsychotics for this population. We also explain medication dosing guidelines and monitoring recommendations.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: Psychosis and Schizophrenia in Children and Adolescents
- Treatment of Psychosis and Schizophrenia in Children and Adolescents: Antipsychotic Dosing, Monitoring, and Side Effects
Are antidepressants in adolescent depression associated with an increased risk for suicidality? In this episode, we discuss the particularities of adolescent depression, including some statistics and the risk of suicide when using antidepressants in this population.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CMEs: Smart Take Vol. 02
- Depression in Adolescents
In this episode, we discuss the diagnosis of psychotic symptoms in children and adolescents, including the differences between primary and secondary psychosis and the rating scales for assessing these symptoms.
Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: Psychosis and Schizophrenia in Children and Adolescents
- Diagnostic Evaluation of Psychotic Symptoms in Children and Adolescents
Can L-methylfolate help in depression treatment? Should we indicate it to all patients with depression? In this episode, we discuss the metabolic pathways for folic acid, when to indicate L-methylfolate, and when to perform genetic testing for methyltetrahydrofolate reductase (MTFR) enzymes.
Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.5 CMEs: Quick Take Vol. 41
- The Potential Use of Folate and Its Derivatives in Treating Psychiatric Disorders: A Systematic Review
Antipsychotics or cholinesterase inhibitors for BPSD?
This episode discusses the evidence of antipsychotics and cholinesterase inhibitors for BPSD, including the risks of using antipsychotics in elderly patients. We also provide recommendations for treating patients with Parkinson’s disease and Lewy body dementia.
Faculty: Lauren Gerlach, D.O.
Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: Management of Behavioral and Psychological Symptoms of Dementia
- Antipsychotics and Cholinesterase Inhibitors for BPSD
What are the safest and most effective medications for depression in youth with bipolar disorder? In this episode, we compare the response rates of quetiapine, olanzapine, and lurasidone for bipolar depression in youth. This episode also explains the differences in metabolic side effects and discusses the limitations of this study.
Faculty: David Rosenberg, M.D.
Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.5 CMEs: Smart Take Vol. 01
- Efficacy and Safety of SGAs in Youth With Bipolar Depression
This episode discusses the pharmacologic treatments for BPSD, including the indications for using psychotropic medications as first-line treatment. It also explains when medications are ineffective and when to use them as a temporary measure.
Faculty: Lauren Gerlach, D.O.
Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: Management of Behavioral and Psychological Symptoms of Dementia
- Overview of Pharmacologic Treatment for BPSD
What are FIASMA psychotropics? What do they have to do with COVID-19? In this episode, we discuss a recent study that compared rates of severe illness among patients who, when admitted for COVID-19, were or were not taking a FIASMA—a functional inhibitor of acid sphingomyelinase activity.
Faculty: Jim Phelps, M.D.
Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.5 CMEs: Quick Take Vol. 40
- Association Between FIASMA Psychotropic Medications and Reduced Risk of Intubation or Death in Individuals With Psychiatric Disorders Hospitalized for Severe COVID-19: An Observational Multicenter Study
Are antipsychotics the answer to the chaos of dementia? In this episode, we discuss the pharmacologic and nonpharmacologic treatment approaches to address BPSD, including the risks of using antipsychotics and the causes of death related to their use.
Faculty: Lauren Gerlach, D.O.
Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: Management of Behavioral and Psychological Symptoms of Dementia
- Pharmacologic and Nonpharmacologic Treatment Approaches
In this episode, we discuss a recent RCT on using brexpiprazole to treat borderline personality disorder. Is it safe and effective? Could brexpiprazole be the magic bullet we were waiting for?
Faculty: Jim Phelps, M.D.
Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.5 CMEs: Quick Take Vol. 40
- A Double-Blind Placebo-Controlled Study of Brexpiprazole for the Treatment of Borderline Personality Disorder
This episode discusses the patient factors underlying BPSD, such as neurodegeneration, acute medical issues, medication changes, pain, and psychiatric diagnoses. It also explains caregiver and environmental factors and the concept of the “broken brain.”
Faculty: Lauren Gerlach, D.O.
Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: Management of Behavioral and Psychological Symptoms of Dementia
- Understanding Patient, Caregiver, and Enviromental Factors
Is it safe to use stimulants in preschool children with ADHD? In this episode, we discuss the long-term symptom control and safety of an ER methylphenidate compound in preschool children 4 to <6 years.
Faculty: David Rosenberg, M.D.
Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.5 CMEs: Smart Take Vol. 1
- Long-Term Treatment With Extended-Release Methylphenidate Treatment in Younger Children
How to determine whether hepatic impairment can affect drug metabolism? This episode discusses practical considerations when prescribing psychotropic medications for patients with hepatic issues. It also clarifies dosing considerations for specific medications, such as clozapine and valproate, in the context of patients with hepatic issues.
Guest: Jonathan Meyer, M.D.
Interviewer: Mohan Gautam, M.D.
Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.5 CMEs: Use of Psychotropics in Patients With Hepatic Issues - Interview with Jonathan M. Meyer, M.D.
How to titrate clozapine in inpatients and outpatients? In this episode, we discuss important considerations for switching to clozapine, including the indications and clinical scenarios for using it. This episode also explains precautions while titrating clozapine and how to reduce the preswitch antipsychotic.
Faculty: Brian Miller, M.D.
Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: Antipsychotic Switching: Intersection of Art and Science
- Important Considerations for Switching to Clozapine
In this episode, we discuss the interventions found to be efficacious in youth with ADHD. Specifically, would treatment with stimulants be effective at reducing irritability in youth with ADHD?
Faculty: Jim Phelps, M.D.
Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.5 CMEs: Quick Take Vol. 39
- A Mini-Review of Pharmacologic and Psychosocial Interventions for Reducing Irritability Among Youth With ADHD
This episode discusses antipsychotic switching from oral antipsychotics to LAIs, including the factors to consider when titrating antipsychotics and establishing PO tolerability before switching to an LAI.
Faculty: Brian Miller, M.D.
Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: Antipsychotic Switching: Intersection of Art and Science
- Types of Antipsychotic Switching: Between PO Agents and From PO to LAI
In this episode, we discuss a systematic review and network analysis that compares 11 medications for treating severe agitation in the emergency department. Which medications have been shown to work best?
Faculty: Jim Phelps, M.D.
Host: Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.5 CMEs: Quick Take Vol. 39
- Rapid Tranquilization of the Agitated Patient in the Emergency Department: A Systematic Review and Network Meta-Analysis
Which is the preferred strategy for switching from one antipsychotic to another?
This episode discusses strategies for antipsychotic switching: Abrupt, cross-taper, taper, and plateau cross-taper switch.
Faculty: Brian Miller, M.D.
Hosts: Jessica Diaz, M.D., Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 1 CME: Antipsychotic Switching: Intersection of Art and Science
- Strategies for Antipsychotic Switching
Are there FDA-approved medications for eating disorders? In this episode, we discuss management strategies for eating disorders, including the use of FDA-approved medications, the importance of cognitive–behavioral interventions, and the need to reduce stigma in these disorders.
Guest: Timothy Brewerton, M.D.
Interviewer: Wegdan Rashad, M.D.
Hosts: Jessica Diaz, M.D.; Richard Seeber, M.D.
- Learn more about our memberships here
- Earn 0.5 CMEs: The Psychopharmacology of Feedingand Eating Disorders - Interviewwith Timothy Brewerton, M.D.,DLFAPA, FAED, DFAACAP, CEDS-S
What are the contraindications to antipsychotic switching? This episode discusses the relative contraindications of antipsychotic switching, including recent recovery from an acute psychotic episode, current stability on an LAI, and history of violence or severe symptoms.
Faculty: Brian Miller, M.D.
Host: Jessica Diaz, M.D.
- Learn more about our memberships here
- Earn 1 CME: Antipsychotic Switching: Intersection of Art and Science
- Relative Contraindications to Antipsychotic Switching
Why do patients stop clozapine?
This episode discusses clozapine discontinuation rates and reasons for doing so among patients who later recommenced clozapine therapy.
Faculty: Jim Phelps, M.D.
Host: Jessica Diaz, M.D.
- Learn more about our memberships here
- Earn 0.5 CMEs: Quick Take Vol. 38
- Demographic and Clinical Characteristics of Patients Who Recommence Clozapine Following Therapy Interruptions
Sharpen your clinical skills with a clinical case of an adolescent girl with OCD. This episode also reviews the progression and consequences of the patient’s symptoms, the diagnosis, and the best treatment options for improving her symptoms.
Faculty: David Rosenberg, M.D.
Host: Jessica Diaz, M.D.
- Learn more about our memberships here
- Earn 1 CME: OCD in Children and Adolescents
- Assessing and Treating Jane
In this episode, Dr. Phelps discusses a study on the efficacy and safety of mirtazapine for treating agitation in patients with dementia. Would prescribing mirtazapine be worth the risk?
Faculty: Jim Phelps, M.D.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 38
- Study of Mirtazapine for Agitated Behaviors in Dementia (SYMBAD): A Randomised, Double-Blind, Placebo-Controlled Trial
Can we use clomipramine in children?
This episode discusses tips for clinicians treating pediatric OCD, follow-up on pediatric OCD symptoms into adulthood, and treatment response in OCD. It also reviews the use of clomipramine for treatment-resistant OCD and its requirements and precautions.
Faculty: David Rosenberg, M.D.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: OCD in Children and Adolescents
- Clinical Tips for Treating Pediatric OCD, Long-Term Follow-Up, and Treatment-Resistant OCD
How should we treat patients with bipolar disorder and comorbid GAD? In this episode, Dr. David Osser discusses an evidence-based treatment algorithm for the treatment of generalized anxiety disorder. He also clarifies common clinical concerns, such as treating GAD in patients with comorbid conditions and treatment resistance.
Guest: David Osser, M.D.
Interviewer: Mohan Gautam, D.O.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: GAD Psychopharmacology Algorithm -Interview with David Osser, M.D.
- Psychopharmacology Algorithms from Psychopharmacology Algorithms Project at the Harvard South Shore Psychiatry Residency Training Program
What are the FDA-approved medications for pediatric OCD? This episode discusses the guidelines for the management of pediatric OCD, including the treatment for mild, moderate, and severe OCD symptoms, as well as the recommended treatment for remission and maintenance, partial response, and nonresponse. It also examines medication dosing guidelines and FDA-approved medications.
Faculty: David Rosenberg, M.D.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: OCD in Children and Adolescents
- Guidelines for the Management of Pediatric OCD
Can ketamine be an effective adjunctive treatment to sustain abstinence from alcohol? In this episode, Dr. Phelps discusses a double-blind, placebo-controlled trial of adjunctive ketamine with mindfulness psychotherapy for treating alcohol use disorder.
Faculty: Jim Phelps, M.D.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 37
- Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder
How to untangle pediatric OCD from ASD and GAD? This episode discusses pediatric OCD and its comorbidities: Depression, GAD, and ASD. It includes a discussion on the differences in concerns between OCD and GAD, the assessment of primary and secondary depressive symptoms, and the differences between ASD and OCD rituals.
Faculty: David Rosenberg, M.D.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: OCD in Children and Adolescents
- Pediatric OCD Comorbidity With Depression, Anxiety Disorders, and ASD
Have you ever imagined using rTMS for patients who struggle to quit smoking?
This episode discusses a double-blind RCT that assessed the efficacy of rTMS in patients with tobacco use disorder who had at least 1 prior failed attempt to quit.
Faculty: Jim Phelps, M.D.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 37
- Repetitive Transcranial Magnetic Stimulation for Smoking Cessation: A Pivotal Multicenter Double‐Blind Randomized Controlled Trial
Learn some of the recommendations from the Handbook of Good Psychiatric Management for Borderline Personality Disorder. This episode addresses the clinical approach and drug management in the good psychiatric management of BPD.
Faculty: Paul Links, M.D.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Pharmacologic Management of BPD: Recent Developments
- Good Psychiatric Management for BPD
How do you distinguish obsessive-compulsive and related disorders from habits? In this episode, we discuss the varying presentations of OCRDs and challenges in their management, including practical recommendations for psychopharmacologic management.
Guest: Robert Hudak, M.D.
Interviewer: Wegdan Rashad, M.D.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Obsessive-Compulsive and Related Disorders - Interview with Robert Hudak, M.D.
What other medications can we offer to our patients with BPD? This episode discusses some novel medication approaches used in borderline personality disorder, including omega-3 fatty acids, methylphenidate, clonidine, doxazosin, memantine, and oxytocin.
Faculty: Paul Links, M.D.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Pharmacologic Management of BPD: Recent Developments
- Omega-3 Fatty Acids, Methylphenidate, Clonidine, Doxazosin, Memantine, and Oxytocin for BPD
Is lithium really effective in patients with a high risk of suicide? In this episode, Dr. Phelps discusses a randomized clinical trial that assessed the efficacy of adding lithium to an existing medication regimen for reducing the rate of suicide-related events in veterans with bipolar disorder and depression.
Faculty: Jim Phelps, M.D.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 36
- Lithium Treatment in the Prevention of Repeat Suicide-Related Outcomes in Veterans With Major Depression or Bipolar Disorder
Are mood stabilizers effective for borderline personality disorder? This episode discusses the use of lamotrigine and lithium in BPD patients, including possible benefits, concerns, and recommendations regarding these medications.
Faculty: Paul Links, M.D.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Pharmacologic Management of BPD: Recent Developments
- Mood Stabilizers for BPD: Lamotrigine and Lithium
Should we target anxiety disorders and sleep-related problems simultaneously? In this episode, Dr. Phelps discusses a narrative review to provide an overview of the evidence of the associations between anxiety disorders and sleep-related problems in children and adolescents.
Faculty: Jim Phelps, M.D.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 36
- Treatment Implications of Sleep‑Related Problems in Pediatric Anxiety Disorders: A Narrative Review of the Literature
This episode discusses the use of antipsychotics in patients with borderline personality disorder, including specific information on quetiapine and clozapine and some tips regarding the use of antipsychotics in these cases.
Faculty: Paul Links, M.D.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Pharmacologic Management of BPD: Recent Developments
- Antipsychotics for BPD
Which medications can we offer for alcohol use disorder? This episode will offer practical tips for selecting and initiating medications for managing patients with at-risk drinking and alcohol use disorder.
Guest: Joji Suzuki, M.D.
Interviewer: Wegdan Rashad, M.D.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: What Clinicians Need to KnowAbout Alcohol Use Disorder -Interview with Joji Suzuki, M.D.
This episode discusses the evidence and benefits of topiramate and stimulant replacement therapy for cocaine use disorder. It also addresses the use of these medications when there are comorbidities, such as alcohol use disorder and ADHD.
Faculty: Andrew Saxon, M.D.
Hosts: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: Experimental Pharmacotherapies for Stimulant Use Disorder
- Topiramate and Methylphenidate for Cocaine Use Disorder and Its Comorbidities
In this episode, we discuss the problem of pre-existing mood disorders increasing the risk of hospitalization and death among people infected with COVID-19. Why does this occur?
Faculty: Jim Phelps, M.D.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 34
- Association Between Mood Disorders and Risk of COVID-19 Infection, Hospitalization, and Death
This episode discusses the evidence of mirtazapine, bupropion, and naltrexone for stimulant use disorder. Are these promising treatments? Are they really effective?
Faculty: Andrew Saxon, M.D.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: Experimental Pharmacotherapies for Stimulant Use Disorder
- Antidepressants and Naltrexone for Methamphetamine Use Disorder
Can we use ketamine as a maintenance treatment for MDD?
In this episode, Dr. Phelps discusses CANMAT’s recommendations for the use of ketamine for MDD.
Faculty: Jim Phelps, M.D.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 35
- The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults With Major Depressive Disorder
Can methylphenidate help amphetamine and methamphetamine use disorder? This episode discusses stimulant replacement therapies for methamphetamine and amphetamine use disorder. This includes the possible use of MPH in patients with underlying ADHD.
Faculty: Andrew Saxon, M.D.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: Experimental Pharmacotherapies for Stimulant Use Disorder
- Stimulant Replacement Therapies for Methamphetamine and Amphetamine Use Disorder
What is the first-line treatment for premenstrual mood syndromes? In this episode, Dr. Lauren Osborne discusses premenstrual mood syndromes and offers valuable insights regarding their management. She also discusses novel medications, such as brexanolone and drospirenone.
Guest: Lauren Osborne, M.D.
Interviewer: Wegdan Rashad, M.D.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Premenstrual Mood Syndromes -Interview with Lauren Osborne, M.D.
This episode discusses the course and prognosis for stimulant use disorder as well as how to diagnose and assess this disorder. It also explains the loss of control over stimulant use, dysfunctional behaviors, co-occurring psychiatric disorders, and medical side effects.
Faculty: Andrew Saxon, M.D.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: Experimental Pharmacotherapies for Stimulant Use Disorder
- Stimulants Use: Course, Assessment, and Diagnosis
Should zuranolone be a first-line treatment for postpartum depression? In this episode, Dr. Phelps discusses a randomized trial of zuranolone—a new neuromodulatory steroid—in the context of previous guidelines for the treatment of postpartum depression.
Faculty: Jim Phelps, M.D.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 35
- Effect of Zuranolone vs Placebo in Postpartum Depression
How long should we continue antipsychotic treatment in FEP? This episode discusses the long-term treatment of FEP, including the duration of antipsychotic treatment and the effects of dose reduction, the pros and cons of antipsychotic treatment, and the importance of collaborative treatment.
Faculty: Stephen Marder, M.D.
Host: Jessica Diaz, M.D.
- Learn more about Premium Membership here
- Earn 0.75 CMEs: Assessment and Management of First Episode of Psychosis
- Long-Term Treatment of FEP
In this episode, Dr. Phelps discusses the recent literature on brain volume changes after first-episode psychosis. What causes brain volume reductions—the illness or antipsychotics?
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 34
- The Effects of Antipsychotic Treatment on the Brain of Patients With First-Episode Schizophrenia: A Selective Review of Longitudinal MRI Studies
Do people with schizophrenia already have a high risk of metabolic effects early in the course of illness? This episode discusses health concerns for first-episode patients, including life expectancy, metabolic conditions in drug-naïve patients, the signs of developing insulin resistance, and the approaches for early metabolic changes.
Faculty: Stephen Marder, M.D.
Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.75 CMEs: Assessment and Management of First Episode of Psychosis
- Health Concerns for First-Episode Patients
This episode discusses treatment-resistant early psychosis, including treatment with LAIs and the use of clozapine for treatment-resistant cases.
Faculty: Stephen Marder, M.D.
Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.75 CMEs: Assessment and Management of First Episode of Psychosis
- Psychopharmacology for People With Treatment-Resistant Early Psychosis
Does adult-onset ADHD really exist? This episode discusses the neurobiological underpinnings of adult ADHD. It also describes how to assess adults with ADHD, important considerations, and some management strategies.
Guest: Oscar Bukstein, M.D.
Interviewer: Mohan Gautam, D.O.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: The Clinical Guide to Adult ADHD -Interview with Oscar Bukstein, M.D., M.P.H.
Is binge eating an addictive disorder or an impulse-control disorder? In this episode, Dr. Phelps summarizes the evidence of efficacy of several medications for binge eating disorder. He also discusses the psychopathology and neuropharmacology of binge eating disorder.
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 33
- Prospects for New Drugs To Treat Binge Eating Disorder: Insights From Psychopathology and Neuropharmacology
This episode discusses considerations when treating first-episode psychosis with antipsychotics, treatment principles and response, and early predictors of poor long-term course.
Faculty: Stephen Marder, M.D.
Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.75 CMEs: Assessment and Management of First Episode of Psychosis
- Management of First Episodes: Antipsychotics
This episode discusses whether clozapine and other medications can reduce the risk of suicide. Is it a "class effect" of antipsychotics, or is it specific to clozapine?
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 33
- Effects on Suicidal Risk: Comparison of Clozapine to Other Newer Medicines Indicated to Treat Schizophrenia or Bipolar Disorder
What are the risks associated with cannabinoid use? This episode discusses some risks, such as overdose, increased ER visits, and cardiovascular risks as well as the effects on pulmonary health.
Faculty: Diana Martinez, M.D.
Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.75 CMEs: Medicinal Cannabis and the Psychiatric Patient: Clinical Harm vs Novel Treatment
- Cannabinoids and Risks for Patients
How do you titrate lithium doses? In this episode, Dr. David Osser discusses practical insights on lithium dosing and monitoring strategies. Guest: David Osser, M.D.
Interviewer: Mohan Gautam, D.O.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Lithium: How to Manage Dosage andSide Effects and Persuade Patients toTake It - Interview with David Osser, M.D.
Can we use CBD for psychiatric disorders?
This episode discusses the evidence for medical uses of CBD for various disorders, such as childhood epilepsy, schizophrenia, social anxiety disorder, opioid use disorder, and cannabis use disorder.
Faculty: Diana Martinez, M.D.
Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.75 CMEs: Medicinal Cannabis and the Psychiatric Patient: Clinical Harm vs Novel Treatment
- Understanding the Evidence for CBD
Do SSRIs really increase suicide risk? This episode discusses the controversial literature regarding the effect of antidepressant initiation on suicidal ideation. Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 32
- Suicidality and Self-Injury With Selective Serotonin Reuptake Inhibitors in Youth: Occurrence, Predictors, and Timing
Does cannabis use cause cognitive deficits? This episode discusses cannabis use and its long-term effects on cognition in adults and younger people. Faculty: Diana Martinez, M.D.
Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.75 CMEs: Medicinal Cannabis and the Psychiatric Patient: Clinical Harm vs Novel Treatment
- Cannabis and Cognition
When should you suspect clozapine-induced myocarditis? Myocarditis has nonspecific manifestations. In this episode, Dr. Phelps explains the clinical presentation and the steps to take if you suspect myocarditis.
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 32
- Clozapine-Induced Myocarditis: Electronic Health Register Analysis of Incidence, Timing, Clinical Markers, and Diagnostic Accuracy
This episode discusses cannabis use in patients with a psychiatric disorder. It also addresses the risk of psychosis in people who use cannabis and the relationship to schizophrenia.
Faculty: Diana Martinez, M.D.
Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.75 CMEs: Medicinal Cannabis and the Psychiatric Patient: Clinical Harm vs Novel Treatment
- Does Cannabis Use Cause Psychiatric Disorders?
When a patient does not respond to an SSRI trial, what is the best strategy—increase the dose, augment with another agent, or switch to another SSRI? In this interview, Dr. Hudak discusses dosing strategies and the treatment of patients with OCD and comorbid psychiatric conditions. Guest: Robert Hudak, M.D.
Interviewer: Mohan Gautam, D.O.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Treatment-Resistant Obsessive-Compulsive Disorder - Interview with Robert Hudak, M.D.
This episode discusses lithium augmentation for psychotic depression, including evidence from different case series and open-label studies. It also addresses some clinical strategies for lithium augmentation.
Faculty: David Osser, M.D.
Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1.25 CMEs: The Psychopharmacology Algorithm for Psychotic Depression
- Node 5: Lithium Augmentation
Which medications can be used for acute and chronic agitation in dementia?
For acute agitation, you might consider the use of haloperidol. For chronic agitation, you could consider citalopram: Its efficacy has been found to be equal to that of antipsychotics in randomized trials.
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 31
- Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions
This episode discusses how to choose an antipsychotic for psychotic depression combination therapy. It also reviews the efficacy and side effects of first- and second-generation antipsychotics and the evidence of SGAs for psychotic depression. Faculty: David Osser, M.D.
Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1.25 CMEs: The Psychopharmacology Algorithm for Psychotic Depression
- Node 2: Choosing an Antipsychotic for Psychotic Depression
COVID-19 infection is associated with new-onset neurological illness but at relatively low absolute rates. On the other hand, rates for new-onset anxiety and mood disorders can be higher, at 7% and 8%, respectively. Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 31
- Six-Month Neurological and Psychiatric Outcomes in 236,379 Survivors of COVID-19: A Retrospective Cohort Study Using Electronic Health Records
Which is the best antidepressant for combination treatment in psychotic depression?
This episode includes the use of venlafaxine plus quetiapine and how to choose an antidepressant for combination treatment. Faculty: David Osser, M.D.
Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1.25 CMEs: The Psychopharmacology Algorithm for Psychotic Depression
- Node 2C: Combination Therapy: SNRIs + Antipsychotics
How can we counsel patients about smoking cessation? In this interview, Dr. Joji Suzuki emphasizes the advantages of motivational interviewing and discusses some pharmacologic treatments, such as nicotine replacement therapies, varenicline, and bupropion.
Guest: Joji Suzuki, M.D.
Interviewer: Wegdan Rashad, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: The Clinical Guide On Tobacco Use Disorder - Interview with Joji Suzuki, M.D.
This episode discusses the use of ECT for severely ill patients, including its benefits and limitations, as well as the use of ECT as a maintenance treatment.
Faculty: David Osser, M.D.
Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1.25 CMEs: The Psychopharmacology Algorithm for Psychotic Depression
- Node 1: ECT for Severely Ill Patients
What was the difference among antipsychotics? Over 1 year, lurasidone caused no net weight gain, whereas olanzapine caused a gain of 10 pounds. Perphenazine was associated with a 2 lb. loss vs olanzapine's 9.5 lb. gain.
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 30
- Comparison of the Metabolic Characteristics of Newer Second-Generation Antipsychotics
This episode discusses first- and second-generation antipsychotics during breastfeeding, including clozapine, the only psychiatric drug nearly always contraindicated.
Faculty: Lauren Osborne, M.D.
Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: Understanding the Use of Psychotropic Drugs in Lactation
- Antipsychotics During Breastfeeding
How effective is fluvoxamine in patients with COVID-19? A 2-week course of full-dose fluvoxamine decreased clinical deterioration in outpatients with symptomatic COVID-19 infection.
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Lorena Rodríguez, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 30
- Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
Can we use antidepressants during breastfeeding? This episode discusses the use of antidepressants during breastfeeding, including SSRIs, TCAs, bupropion, and mirtazapine.
Faculty: Lauren Osborne, M.D.
Hosts: Jessica Diaz, M.D.; Lorena Rodríguez M.D.
- Learn more about Premium Membership here
- Earn 1 CME: Understanding the Use of Psychotropic Drugs in Lactation
- Antidepressants During Breastfeeding
Is it safe to use atypical antipsychotics for insomnia? Can we use benzodiazepines? This podcast features the different treatments for acute and chronic insomnia. It also addresses the differential diagnoses and some treatment options for insomnia and comorbid depressive disorders.
Guest: Charles Reynolds M.D.
Interviewer: Mohan Gautam D.O.
Hosts: Jessica Diaz, M.D.; Lorena Rodríguez, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: The Clinical Guide to Sleep Issues in Psychiatry - Interview with Charles F. Reynolds III, M.D.
When it comes to drug use while breastfeeding, what really matters is not the infant dose but the effect on the infant. This episode discusses drug use in breastfeeding, common adverse reactions, and their relationship to maternal dosing.
Faculty: Lauren Osborne, M.D.
Hosts: Jessica Diaz, M.D.; Lorena Rodríguez M.D.
- Learn more about Premium Membership here
- Earn 1 CME: Understanding the Use of Psychotropic Drugs in Lactation
- Drug Use in Breastfeeding and Adverse Effects
A novel medication approach for borderline personality disorder is discussed. In this meta-analysis of fish oil for borderline personality disorder, the effect size relative to placebo was 0.54 (substantial) and for affective dysregulation was 0.74 (clinically very relevant).
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Lorena Rodríguez, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 29
- Marine Omega-3 Fatty Acid Supplementation for Borderline Personality Disorder: A Meta-Analysis
This episode discusses drug use in breastfeeding and how to estimate infant exposure with the milk-to-plasma ratio and the relative infant dose. Learn when these calculations can be helpful.
Faculty: Lauren Osborne, M.D.
Hosts: Jessica Diaz, M.D.; Lorena Rodríguez M.D.
- Learn more about Premium Membership here
- Earn 1 CME: Understanding the Use of Psychotropic Drugs in Lactation
- Estimating Infant Exposure
When tapering antipsychotics, conceptualize the process as "finding a new minimum effective dose." This could take months, likely years. This episode features some dose examples.
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 29
- A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
This episode discusses the prevalence and management of psychiatric comorbidities with alcohol use disorder. Learn some strategies for treating alcohol use disorder and comorbid depressive and anxiety disorders.
Faculty: Joji Suzuki, M.D.
Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.
- Learn more about Premium Memberships here
- Earn 1 CME: What Clinicians Need to Know About Alcohol Use Disorder
- Psychiatric Comorbidities With Alcohol Use Disorder: Prevalence and Management
If your patient has perimenopausal depression, what are the treatment options? This podcast explains different treatment options, such as antidepressants, hormone therapy, and psychotherapy. It also addresses some strategies for managing vasomotor symptoms.
Guest: Vivien Burt, M.D.;
Interviewer: Mohan Gautam, D.O.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Blue Moods and Hot Flashes: Treating Perimenopausal Depression - Interview with Vivien K. Burt, M.D., Ph.D.
This episode discusses medications for alcohol use disorder, such as naltrexone, acamprosate, and disulfiram. It explains their clinical effects, the goals and benefits of treatment, side effects, liver function monitoring, precautions, contraindications, and dosing. Finally, it emphasizes the patient factors to consider when choosing a treatment.
Faculty: Joji Suzuki, M.D.
Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.
- Learn more about Premium Memberships here
- Earn 1 CME: What Clinicians Need to Know About Alcohol Use Disorder
- Pharmacology in Alcohol Use Disorder: Naltrexone, Acamprosate, and Disulfiram
From the various references cited in this episode, the metamessage is clear: Thyroid hormone belongs in the treatment toolkit of psychiatric specialists, and monitoring of TSH is our responsibility.
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Memberships here
- Earn 0.5 CMEs: Quick Take Vol. 28
- Increased Prevalence of Subclinical Hypothyroidism and Thyroid Autoimmunity in Depressed Adolescents: Results From a Clinical Cross-Sectional Study in Comparison to the General Pediatric Population
This episode discusses the 3 approaches in the treatment of substance use disorders: Medications for alcohol use disorder, counseling, and 12-Step facilitation.
Faculty: Joji Suzuki, M.D.
Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.
- Learn more about Premium Memberships here
- Earn 1 CME: What Clinicians Need to Know About Alcohol Use Disorder
- Clinical Principles on Managing Alcohol Use Disorder
Previous recommendations and even APA guidelines have suggested that electroconvulsive therapy for depression is not as effective for patients with borderline personality disorder as it is for those without. This retrospective analysis of data from McLean Hospital suggests this assumption is not correct.
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Memberships here
- Earn 0.5 CMEs: Quick Take Vol. 28
- Treatment Outcomes of Electroconvulsive Therapy for Depressed Patients With and Without Borderline Personality Disorder: A Retrospective Cohort Study
This episode discusses alcohol withdrawal symptoms and consequences, including delirium tremens, management of alcohol withdrawal, and when to use symptom-triggered therapy or fixed-dose regimens.
Faculty: Joji Suzuki, M.D.
Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.
- Learn more about Premium Memberships here
- Earn 1 CME: What Clinicians Need to Know About Alcohol Use Disorder
- Consequences of Alcohol Use Disorder: Withdrawal
Laboratory testing is essential in the practice of psychopharmacology. For example, which parameters should be monitored in patients taking carbamazepine, TCAs, atypical antipsychotics, or esketamine?
Guest: Sandra Jacobson, M.D.;
Interviewer: Mohan Gautam., D.O.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Laboratory Testing in the Practice of Psychopharmacology - Interview with Sandra A. Jacobson, M.D.
This episode discusses technology-facilitated adherence enhancement, including text messaging, a wireless system to track adherence, and the evidence of technology-facilitated adherence for patients with bipolar disorder. It also addresses an ecological momentary intervention and the involvement of family in treatment adherence.
Faculty: Martha Sajatovic, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Memberships here
- Earn 1 CME: Psychotropic Drug Adherence
- Technology-Facilitated Adherence Enhancement and Family Involvement
When a patient presents with markedly elevated temperature and altered mental status, is it neuroleptic malignant syndrome or serotonin syndrome? If you do not have a medication list, some clinical signs may help.
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Memberships here
- Earn 0.5 CMEs: Quick Take Vol. 27
- Drug-Induced Hyperthermic Syndromes in Psychiatry
This episode discusses how to improve psychotropic drug adherence by targeting the reasons for nonadherence. It also discusses a 3-tiered approach to enhancing adherence, a patient questionnaire to evaluate the reasons for not taking medications, the top reasons for poor antipsychotic adherence, and the positive aspects of taking medications. Finally, it explains other approaches to improve adherence, such as simplifying the dosing regimen.
Faculty: Martha Sajatovic, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Memberships here
- Earn 1 CME: Psychotropic Drug Adherence
- Improving Psychotropic Drug Adherence: Targeting Reasons for Nonadherence and the 3-Tiered Approach to Enhancing Adherence
How risky is esketamine? In this episode, we examine the safety of esketamine using postmarketing data that have been reported since the drug was approved and released.
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Memberships here
- Earn 0.5 CMEs: Quick Take Vol. 27
- Postmarketing Safety Concerns With Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
This episode discusses an algorithm for assessing adherence; the reasons for suboptimal adherence, including adverse drug reactions; measuring perceived side effects with the FIBSER scale; and how to help individuals communicate with providers about side effects.
Faculty: Martha Sajatovic, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Memberships here
- Earn 1 CME: Psychotropic Drug Adherence
- Nonadherence: Adverse Drug Reactions, Measuring Perceived Side Effects With FIBSER, and Communication About Side Effects
Delirium has been frequently found in patients who test positive for COVID-19. It has additional features that we do not typically see in ordinary delirium. The critical question is: How do you manage these patients?
Guest: Scott Beach, M.D.
Interviewer: Wegdan Rashad, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Neurocovid: Pharmacological recommendations for delirium associated with COVID-19 - Interview with Scott R. Beach, M.D.
This episode discusses the assessment of adherence: Self-report, electronic medication monitoring systems, rating scales, medication possession ratio, questions for assessing medication adherence, and the recommended frequency of adherence monitoring.
Faculty: Martha Sajatovic, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Memberships here
- Earn 1 CME: Psychotropic Drug Adherence
- Assessing Adherence: Self-Report, Rating Scales, Medication Refills, Automated Pill-Taking Frequency Monitoring, Medication Routines, and Duration of Assessments
A new randomized trial suggests that the efficacy of antidepressants for the treatment of bipolar depression is no greater than placebo. This tips the meta-analytic balance scale, which already pointed in this direction.
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Memberships here
- Earn 0.5 CMEs: Quick Take Vol. 26
- Citalopram for Acute and Preventive Efficacy in Bipolar Depression (CAPE-BD): A Randomized, Double-Blind, Placebo-Controlled Trial
This podcast offers a discussion on catatonia and delirium as well as treatments for their co-occurrence. Treatments discussed include benzodiazepines, amantadine, and memantine. We also address the management of COVID-19 delirium with antipsychotics.
Faculty: Scott Beach, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Memberships here
- Earn 1 CME: Management of Delirium
- Special Considerations in Delirium: Catatonia and COVID-19
Is psilocybin a potential treatment for major depression? There's certainly been a lot of press coverage, but to date, the reports are largely open trials in a variety of conditions, including OCD, substance use, PTSD, and patients with cancer and psychological distress. Against that backdrop, a randomized trial of psilocybin for major depression is an exciting new step.
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Memberships here
- Earn 0.5 CMEs: Quick Take Vol. 26
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
This podcast features a discussion on the need to highlight anhedonia and anergia as core symptoms of depression. We also cover the clinical utility of MAOIs in treating patients with melancholic or biological depression and Parkinson's disease.
Guest: Ken Gillman, M.D.;
Interviewer: Wegdan Rashad, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Dopamine and Depression: Clinical Considerations - Interview with Ken Gillman, M.D.
This podcast offers a discussion on the use of antipsychotics for managing delirium. Topics covered include: Choosing an antipsychotic, the advantages of IV haloperidol, different dosing strategies, and concerns regarding QT prolongation. We also examine chlorpromazine, olanzapine, quetiapine, and aripiprazole for managing delirium.
Faculty: Scott Beach, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Memberships here
- Earn 1 CME: Management of Delirium
- Haloperidol, Chlorpromazine, and Atypical Antipsychotics for Managing Delirium
First-line treatments for child and adolescent depression are cognitive–behavioral therapy, interpersonal therapy, fluoxetine, and escitalopram.
What works besides routine first-line approaches? This episode discusses options to consider: Pharmaceuticals, nutraceuticals, somatomotor techniques (e.g., yoga), and neuromodulatory tools (e.g., ECT and TMS).
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Memberships here
- Earn 0.5 CMEs: Quick Take Vol. 25
- New Somatic Treatments for Child and Adolescent Depression (Part 1)
This episode discusses nonpharmacologic management strategies for delirium, such as the ones included in the ABCDE bundle.
Faculty: Scott Beach, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Memberships here
- Earn 1 CME: Management of Delirium
- Management of Delirium: Nonpharmacologic Strategies
Are there any alternative medicine treatments that might be useful for your geriatric patients? We examine the evidence base for diet, herbal and nutritional supplements, and mind–body therapies for the prevention of dementia and the treatment of depression.
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Memberships here
- Earn 0.5 CMEs: Quick Take Vol. 25
- Emerging Complementary and Integrative Therapies for Geriatric Mental Health
This episode discusses the assessment of delirium. This includes: EEG and neurological exam, cognitive dysfunctions present in delirium, recommended testing, differential diagnoses, and the consequences of delirium.
Faculty: Scott Beach, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Memberships here
- Earn 1 CME: Management of Delirium
- Delirium: Assessment, Consequences and Sequelae
A meta-analysis of antidepressant doses and responses finds no evidence of improved outcomes with higher doses, just more side effects. However, this conclusion is based on fixed-dose comparison studies, which do not mirror the way we practice. Here we'll compare the lack of evidence for a dose-response relationship to your clinical practice.
Faculty: Jim Phelps
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 24
- In Search of a Dose-Response Relationship in SSRIs—A Systematic Review, Meta-Analysis, and Network Meta-Analysis
This episode discusses valproate kinetics and sublinear kinetics, valproic acid levels, its absolute contraindications, and what to consider when using the package insert.
Faculty: Jonathan Meyer, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: Use of Psychotropics in Patients With Hepatic Issues
- Valproate/Divalproex: Metabolism, Kinetics, and Warnings
A practical discussion on akathisia, extrapyramidal symptoms (EPS), tardive syndromes, and acute dystonia.
Guest: Gregory Pontone, M.D.
Interviewer: Mohan Gautam, D.O.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Drug-Induced Movement Disorders: The Clinical Essentials - Interview with Gregory Pontone, M.D.
This episode discusses the Child-Pugh scale to assess hepatic impairment. It also covers the FDA's position on the inclusion of drug metabolism data for various Child-Pugh stages and cirrhosis.
Faculty: Jonathan Meyer, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: Use of Psychotropics in Patients With Hepatic Issues
- The Importance of Child-Pugh Classification for Staging Hepatic Impairment
Clozapine blood levels can be influenced by many factors. These include dose, gender, age, body weight, caffeine, medications, and of course, smoking.
How much is the reduction in clozapine levels actually due to cigarette smoking?
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 24
- Impact of Smoking Behavior on Clozapine Blood Levels—A Systematic Review and Meta-Analysis
This episode discusses the Child-Pugh Rating Scale and how to interpret it, two clinical cases, and the use of paliperidone and lurasidone in patients with hepatic impairment (Child-Pugh C).
Faculty: Jonathan Meyer, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: Use of Psychotropics in Patients With Hepatic Issues
- Rating Scales for Hepatic Dysfunction: Child-Pugh
How should we approach the management of neuroleptic malignant syndrome? What is the role of bromocriptine, dantrolene, and ECT?
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 23
- The Neuroleptic Malignant Syndrome—A Systematic Case Series Analysis Focusing on Therapy Regimes and Outcome
How important are ALT and AST abnormalities when prescribing psychotropics? Should you adjust dosing in patients with elevated ALT and AST? Does inflammation alter drug kinetics?
Faculty: Jonathan Meyer, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: Use of Psychotropics in Patients With Hepatic Issues
- Diagnosis and Impact on Drug Metabolism of Nonalcoholic Fatty Liver Disease: Steatosis and Nonalcoholic Steatohepatitis
This meta-analysis is a useful reminder of risk factors to look for in your patients. You can also help them understand the long-term risks of Alzheimer's disease.
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 23
- Evidence-Based Prevention of Alzheimer's Disease: Systematic Review and Meta-Analysis of 243 Observational Prospective Studies and 153 Randomised Controlled Trials
How can you assess binge eating disorder? Which is the preferred screening instrument? What is the role of SSRIs, TCAs, and duloxetine?
Faculty: Timothy D. Brewerton, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: The Psychopharmacology of Feeding and Eating Disorders
- Binge Eating Disorder (BED): Diagnosis and Treatment Overview
What are the best treatment options for severe depression with melancholic features? Can you augment tricyclics? What is the preferred option for depression with mixed features?
Guest: David Osser, M.D.
Interviewer: Mohan Gautam, D.O.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.75 CMEs: An Algorithm for the Psychopharmacology of Unipolar Nonpsychotic Depression - Interview with David Osser, M.D.
When should you suspect bulimia nervosa? What is the role of antidepressants, topiramate, and ondansetron?
Faculty: Timothy D. Brewerton, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: The Psychopharmacology of Feeding and Eating Disorders
- Bulimia Nervosa (BN): Diagnosis and Treatment Overview
What are the best treatment options for primary insomnia? What is the role of behavioral therapy and zolpidem?
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 22
- Effectiveness of Sequential Psychological and Medication Therapies for Insomnia Disorder: A Randomized Clinical Trial
What diagnostic considerations should we keep in mind with anorexia nervosa? What are the most effective medications? Does zinc depletion play a role?
Faculty: Timothy D. Brewerton, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: The Psychopharmacology of Feeding and Eating Disorders
- Never Too Thin: Anorexia Nervosa (AN) Diagnosis and Overview of Pharmacological Treatment
What is the role of pharmacotherapy in borderline personality disorder? Is there evidence supporting the use of antidepressants? Which antipsychotic can be helpful? Is lamotrigine effective?
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 22
- Pharmacotherapy for Borderline Personality Disorder: An Update of Published, Unpublished, and Ongoing Studies
What is ARFID (Avoidant/Restrictive Food Intake Disorder)? Are antidepressants helpful? What is the role of adjunctive olanzapine?
Faculty: Timothy D. Brewerton, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: The Psychopharmacology of Feeding and Eating Disorders
- Food Avoidance: Diagnosis and Treatment of Avoidant/Restrictive Food Intake Disorder (ARFID)
Do you treat older patients with bipolar disorder the same as younger patients? What is the optimal lithium dose? What is the role of second-generation antipsychotics such as quetiapine?
Guest: Martha Sajatovic, M.D.
Interviewer: Mohan Gautam, D.O.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Bipolar Disorder in Later Life - Interview with Martha Sajatovic, M.D.
How to assess prolonged grief? Is there a specific therapy? Is there a role for methylphenidate?
Faculty: Charles F. Reynolds III, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: Evidence-Based Treatment of Major Depressive Episodes in Later Life
- Bereavement and Terminal Illness in Later-Life Depression: Complicated Grief and Palliative and Supportive Care
Four different changes in cardiac function are associated with anorexia nervosa. All of them generally resolve if weight restoration can be achieved.
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Plus Membership here
- Earn 0.5 CMEs: Quick Take Vol. 21
- Cardiac Abnormalities Identified With Echocardiography in Anorexia Nervosa: Systematic Review and Meta-Analysis
Can you combine donepezil with antidepressants in later-life depression? What are the benefits? What is the downside?
Faculty: Charles F. Reynolds III, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: Evidence-Based Treatment of Major Depressive Episodes in Later Life
- Long-Term Treatment in Later- Life Depression: Maintenance, Adverse Effects, and Combination of Antidepressants and Donepezil
In schizophrenia, which antipsychotics cause the most weight gain, cholesterol, or glucose increases? Which antipsychotics cause the least? Although a new study may not change your list much, there are some surprises in this episode.
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CME: Quick Take Vol. 21
- Comparative Effects of 18 Antipsychotics on Metabolic Function in Patients With Schizophrenia, Predictors of Metabolic Dysregulation, and Association With Psychopathology: A Systematic Review and Network Meta-Analysis
- What do you do when your patient does not achieve remission?
- What are the best augmentation strategies?
Faculty: Charles F. Reynolds III, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: Evidence-Based Treatment of Major Depressive Episodes in Later Life
- Algorithm for Later-Life Depression Treatment: Antidepressants and Psychotherapy
- What is the role of N-Acetylcysteine (NAC) for hair-pulling and skin-picking Disorders?
- Should NAC be used as a first-line treatment?
Faculty: Robert Hudak, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: Obsessive-Compulsive and Related Disorders
- Pharmacologic Treatment of Hair-Pulling and Skin-Picking Disorders: SSRIs, N-Acetylcysteine and, Riluzole
- Can clozapine increase the risk of COVID-19 infection?
- What is the role of hypersalivation?
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CME: Quick Take Vol. 19
- Clozapine Treatment and Risk of COVID-19
- What is the role of SSRIs for body dysmorphic disorder?
- Should you prescribe antipsychotics?
- What are the most powerful medications for patients with delusional insight?
Faculty: Robert Hudak, M.D.
Host: Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: Obsessive-Compulsive and Related Disorders
- Body Dysmorphic Disorder: Medications, CBT, and Exposure Response Prevention Therapy
- What's an optimal treatment of depression according to a network meta-analysis?
- Should psychotherapy alone be a default first option?
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CME: Quick Take Vol. 18
- A Network Meta-Analysis of the Effects of Psychotherapies, Pharmacotherapies, and Their Combination in the Treatment of Adult Depression
- What are the clinical features of body dysmorphic disorder?
- How can you body dysmorphic disorder? Tips for screening.
Faculty: Robert Hudak, M.D.
Hosts: Jessica Diaz, M.D. ; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: Obsessive-Compulsive and Related Disorders
- Body Dysmorphic Disorder: DSM- 5 Criteria and Clinical Features
- Oral contraceptives can have an impact on mood in women with a history of depression.
- Can they also mimic the effects of chronic psychological stress?
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 18
- Evidence for Stress-Like Alterations in the HPA Axis in Women Taking Oral Contraceptives
What are the clinical features of hoarding disorder? How can you assess hoarding disorder? Tips for screening. What other comorbidities should you consider?
Faculty: Robert Hudak, M.D.
Host: Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: Obsessive-Compulsive and Related Disorders
- Hoarding Disorder: DSM-5 Criteria, Clinical Features, Epidemiology, and Comorbidities
Are long-acting injectable antipsychotics better than oral antipsychotics for preventing relapse and re-hospitalization in schizophrenia?
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CME: Quick Take Vol. 17
- Long-Acting Injections in Schizophrenia: A 3-Year Update on Randomized Controlled Trials Published January 2016–March 2019
- How bad are valproic acid effects in the newborn?
- Is there a role for carbamazepine and oxcarbazepine?
- How to prescribe lamotrigine during pregnancy?
Faculty: Wendy Marsh, M.D.
Hosts: Jessica Diaz, M.D; Flavio Guzman, M.D.
- Prescribing Antiepileptic Drugs for Bipolar Disorder During Pregnancy: Valproate, Carbamazepine, and Lamotrigine
- Earn 1 CME: Clinical Management of Bipolar Disorder in Pregnancy
- Learn more about Premium Membership here
Is transcranial direct current stimulation for negative symptoms of schizophrenia a good idea?
Faculty: Jim Phelps, M.D.
Host: Flavio Guzman, M.D.
Links
- Efficacy and Safety of Transcranial Direct Current Stimulation for Treating Negative Symptoms in Schizophrenia
- Earn 0.5 CME: Quick Take Vol. 16
- Learn more about Premium Membership here
- How safe are first-generation antipsychotics in pregnancy?
- What's their teratogenicity risk?
- How safe are second-generation antipsychotics?
- Are risks dose-dependent?
- What glucose test should you order and when?
Faculty: Wendy Marsh, M.D.
Hosts: Jessica Diaz, M.D; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: Clinical Management of Bipolar Disorder in Pregnancy
- Prescribing Lithium During Pregnancy: Pharmacokinetics, Dosing, and Monitoring
Omega-3 fatty acids have been shown in some randomized trials to be more effective than placebo in the treatment of depression, but a Cochrane review concluded that they are no better than placebo. Should you suggest omega-3 fatty acids for patients with depression? If so, what dose should you recommend?
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CME: Quick Take Vol. 17
- Omega-3 and Polyunsaturated Fat for Prevention of Depression and Anxiety Symptoms: Meta-Analyses of Randomized Trials
- How does pregnancy affect lithium pharmacokinetics?
- How do lithium levels fluctuate across the first, second, and third trimesters?
- How often should you monitor lithium blood levels?
- Should you stop lithium prior to labor?
Faculty: Wendy Marsh, M.D.
Hosts: Jessica Diaz, M.D; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: Clinical Management of Bipolar Disorder in Pregnancy
- Prescribing Lithium During Pregnancy: Pharmacokinetics, Dosing, and Monitoring
- Can e-cigarettes help in smoking cessation?
- What are the main disadvantages of e-cigarettes?
- What is a dual user?
Faculty: Joji Suzuki, M.D.
Hosts: Jessica Diaz, M.D; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME: The Clinical Guide On Tobacco Use Disorder
- Using E-Cigarettes: What Clinicians Must Know
- Should psychiatrists prescribe oral contraceptives?
- What is the role of oral contraceptives in the treatment of PMDD?
- How do oral contraceptives work in premenstrual syndromes?
Faculty: Lauren Osborne, M.D.
Hosts: Jessica Diaz, M.D; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME- "Premenstrual Mood Syndromes"
- Hormonal Treatments for Premenstrual Syndromes: Oral Contraceptives, GnRH Agonists, and Oophorectomy
What can we conclude from 9 international guidelines addressing the role of antidepressants in the treatment of bipolar depression? Can antidepressants induce treatment resistance? Some authoritative authors say, maybe.
Research editor: James Phelps, M.D.
Hosts: Jessica Diaz, M.D; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 0.5 CMEs: Quick Take Vol. 16
- Evaluating the Efficacy and Safety of Antidepressants in Patients With Bipolar Disorder
- Which antidepressant class is effective for the premenstrual syndromes PMS and PMDD?
- How can you use antidepressants intermittently to relieve PMS symptoms (luteal-phase and symptom-onset dosing)?
- Should you prescribe only antidepressants that have been approved by the FDA for PMDD?
Faculty: Lauren Osborne, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME- "Premenstrual Mood Syndromes"
- Psychopharmacology for PMS and PMDD: Luteal Phase Dosing and Choosing Among SSRIs
Atomoxetine is the only non-stimulant medication approved by the FDA for the treatment of ADHD in adults.
We discuss:
- Its most common and not-so-common side effects.
- What other non-stimulants you can use.
Faculty: Oscar Bukstein, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME- "The Clinical Guide to Adult ADHD"
- Nonstimulant Treatments for Adult ADHD: Atomoxetine, Bupropion, Alpha Agonists, and Others
- What is the most helpful and accurate way of understanding premenstrual mood symptoms?
- What is the preferred scale available? Does it have any limitations?
- Are period tracking apps useful for diagnosing PMDD?
Faculty: Lauren Osborne, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME- "Premenstrual Mood Syndromes"
- Clinical Assessment and Diagnosis of Premenstrual Mood Syndromes and Prospective Rating Scales
- What is preferred: Long-acting or short-acting formulations?
- What are the general prescribing principles for all psychostimulants?
- What are their most common side effects?
- What side effects you should monitor?
Faculty: Oscar Bukstein, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME- "The Clinical Guide to Adult ADHD"
- Psychostimulants for Adult ADHD: Formulations, Prescribing Tips, Adverse Effects and Monitoring
- Can smoking affect psychotropic levels?
- What are the two antipsychotics most commonly affected by smoking?
- Which is the antidepressant most commonly affected by smoking?
Faculty: Joji Suzuki, M.D.
Hosts: Jessica Diaz, M.D. ; Flavio Guzman, M.D.
- Learn more about Premium Membership here
- Earn 1 CME- "The Clinical Guide to Tobacco Use Disorder"
- Watching out for Tobacco–Drug Interactions: Pharmacokinetics, Pharmacodynamics and Deinduction
In this episode, we discuss cognitive impairment and sexual problems with lithium.
Here are some question we cover:
- How should you discuss cognitive complaints with your patients?
- What does neuropsychological testing tell us about cognitive impairment with lithium?
- What strategies can you use to mitigate the sexual side effects of lithium?
Faculty: David Osser, M.D.
- Learn more about Premium Membership here
- Earn 1.5 CMEs - "Lithium: How to Manage Dosage and Side Effects and Persuade Patients to Take It"
- Cognitive Impairment and Sexual Problems With Lithium
This interview discusses the use of lithium, thyroid hormone, second-generation antipsychotics, newer antidepressants, and ketamine/esketamine as adjunctive agents in managing major depressive disorder.
Faculty: Michael Thase, M.D. * Learn more about Premium Membership here * Earn 0.75 CMEs - "Top 10 Drug Combinations in MDD - Interview with Prof. Michael E. Thase"
This interview discusses the use of MAOIs and tricyclic antidepressant combinations, adjunctive benzodiazepines and trazodone, and the use of psychostimulants as adjunctive agents in managing major depressive disorder.
Faculty: Michael Thase, M.D. * Learn more about Premium Membership here * Earn 0.75 CMEs - "Top 10 Drug Combinations in MDD - Interview with Prof. Michael E. Thase"
Today's episode is about the management of tardive dyskinesia.
Here are some questions we cover in this episode:
- What is the best way to approach tardive dyskinesia? This episode will discuss an algorithm with levels of evidence for each treatment option.
- What is the evidence level for second-generation VMAT-2 inhibitors, such as deutetrabenazine and valbenazine?
- Is there evidence for prescribing anticholinergics in tardive dyskinesia? Should you use them?
- What options do you have if a VMAT inhibitor is not effective or well tolerated?
Faculty: Greg Pontone, M.D.
- Learn more about Premium Membership here
- Earn 1.25 CMEs: "Drug-Induced Movement Disorders: The Clinical Essentials"
- Treating Tardive Dyskinesia: A Clinical Conundrum and New Approaches
In this episode, we discuss weight gain and GI side effects due to lithium.
Here are some questions we cover:
- What are the causes of weight gain from lithium?
- How should you help patients manage their weight gain?
- What are the most common gastrointestinal side effects?
- How should you manage patients’ gastrointestinal side effects?
Faculty: David Osser, M.D.
- Learn more about Premium Membership here
- Earn 1.5 CMEs - "Lithium: How to Manage Dosage and Side Effects and Persuade Patients to Take It"
- How to Manage GI Side Effects and Weight Gain Due to Lithium?
This episode will offer practical guidance and answer questions about how to interpret abnormal liver function tests in a patient taking psychotropic medications.
Faculty: Sandra Jacobson, M.D.
- Learn more about Premium Membership here
- Earn 0.75 CMEs: Laboratory Testing in the Practice of Psychopharmacology
- Interpreting Liver Function Tests
In this episode, we discuss the diagnosis and management of extrapyramidal symptoms.
Here are some questions Dr. Pontone addresses:
- Are there any biomarkers or neuroimaging studies that help us differentiate drug-induced EPS from Parkinson’s disease?
- What can you do after you identify extrapyramidal symptoms? What should be your first step?
- Is it okay to use anticholinergic agents prophylactically?
- What is the prognosis for extrapyramidal symptoms?
- How long does it typically take for extrapyramidal symptoms to remit?
Faculty: Greg Pontone, M.D.
- Learn more about Premium Membership here
- Earn 1.25 CMEs: "Drug-Induced Movement Disorders: The Clinical Essentials"
- Clinical Pointers on Managing Extrapyramidal Symptoms
Today's episode is about treatment strategies for postpartum bipolar disorder and psychosis. Here are some questions we cover in this episode:
- What is the role for lithium in postpartum psychosis?
- What do we know about mood stabilizers and breastfeeding?
- Is it possible for women who are using lithium to breastfeed in a safe manner?
- If your patient is already on a mood stabilizer, should she switch medications specifically for breastfeeding?
Faculty: Marlene Freeman, M.D.
- Learn more about Premium Membership here
- Earn 1.25 CMEs - "The Clinician's Guide to Postpartum Mood Disorders"
- Postpartum Psychosis: Clinical Considerations
Here are some practical things you’ll learn if you listen to this entire episode:
- Specific tests that you need to order before prescribing lithium (baseline testing).
- How to start lithium.
- The best way to distribute dosing to prevent kidney damage.
- The most relevant drug interactions that may affect lithium levels.
Faculty: David Osser, M.D.
- Learn more about Premium Membership here
- Earn 1.5 CMEs - "Lithium: How to Manage Dosage and Side Effects and Persuade Patients to Take It"
- Baseline Testing and Dosing of Lithium
Antipsychotic-induced weight gain is a huge problem. Today's episode will remind you of some important concepts from the general medicine perspective.
This episode will help you be more systematic about the diagnosis of metabolic syndrome in your clinical practice. It will also give you a framework for monitoring metabolic side effects when you prescribe second-generation antipsychotics.
Faculty: Sandra Jacobson, M.D.
- Learn more about Premium Membership here
- Earn 0.75 CMEs: Laboratory Testing in the Practice of Psychopharmacology
- Gary C.: Antipsychotic-Induced Weight Gain, Hyperlipidemia, and Metabolic Syndrome
In this episode, we discuss the diagnosis and management of akathisia. Here are some questions Dr. Pontone addresses:
- Why is akathisia important?
- For differential diagnosis, what are the most common conditions that can mimic akathisia?
- What is pseudoakathisia?
- What can you do to treat akathisia before adding any new medication?
- If you need to add a medication, which one should you choose?
Faculty: Greg Pontone, M.D.
- Learn more about Premium Membership here
- Earn 1.25 CMEs: "Drug-Induced Movement Disorders: The Clinical Essentials"
- Akathisia: How to Diagnose and Manage?
Today's episode is about the diagnosis of postpartum psychosis. Here are some important questions we cover in this episode:
- How common is postpartum psychosis?
- What underlying etiology should we always suspect?
- How do we differentiate postpartum psychosis from obsessive-compulsive disorder in the postpartum?
- Is postpartum psychosis an emergency, or can it be handled with outpatient treatment?
Faculty: Marlene Freeman, M.D.
- Learn more about Premium Membership here
- Earn 1.25 CMEs: The Clinician's Guide to Postpartum Mood Disorders
- Postpartum Psychosis: Clinical Considerations
This episode explores a clinical trial on the use of hypnotics in insomnia associated with suicidal depression.
- Download a PDF of this interview here
- Become a premium member of the Psychopharmacology Institute
In this podcast, we discuss behavioral and psychopharmacologic management strategies for COVID-19–related delirium. * Download a PDF of this interview here * Become a premium member of the Psychopharmacology Institute
We discuss a study on the use of the mu-opioid receptor antagonist, samidorphan for olanzapine-induced weight gain, compared to placebo and naltrexone.
- Earn 0.5 CME here
- Become a premium member of the Psychopharmacology Institute
We discuss the prevalence and treatment of depression, psychosis in patients with Parkinson’s Disease. * Download a PDF of this interview here * Become a premium member of the Psychopharmacology Institute
We review a study on the management of psychiatric disturbances in Parkinson’s Disease and atypical parkinsonisms. * Download a PDF of this interview here * Become a premium member of the Psychopharmacology Institute
A 14-year-old patient with autism spectrum disorder presents to the emergency room with aggressive and agitated behavior. We discuss possible etiologies and psychosocial and pharmacologic management.
- Download a PDF of this interview here
- Become a premium member of the Psychopharmacology Institute
We review the BAART trial on risperidone vs aripiprazole in irritability associated with autism spectrum disorder. * Download a PDF of this interview here * Become a premium member of the Psychopharmacology Institute
We discuss studies on the safety of antidepressants in pregnancy regarding autism risk, IQ, cardiac malformations, miscarriage, and neonatal mortality.
- Download a PDF of this interview here
- Become a premium member of the Psychopharmacology Institute